CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10148859,101488592,2,F,201007,20170608,20140502,20170620,EXP,,CA-009507513-1404CAN014456,MERCK,,44,YR,,M,Y,,,20170620,,CN,CA,CA,EFAVIRENZ,Asthenia;Drug interaction;Dysarthria;Gait disturbance;Slow speech;Somnolence,101488592,HO,,,101488592,1,200710,200810,,,101488592,1,HIV infection
10377280,103772806,6,F,20060512,20170408,20140812,20170413,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14021034,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20170413,,MD,JP,JP,EFAVIRENZ,Blood glucose increased;Hypercholesterolaemia;Nephrolithiasis,103772806,OT,,,103772806,1,20060125,20120523,,,103772806,1,HIV infection
11825928,118259283,3,F,,20170404,20151211,20170417,EXP,,RS-SUN PHARMACEUTICAL INDUSTRIES LTD-2015R1-107725,RANBAXY,"DESPOTOVIC A, SAVIC B, SALEMOVIC D, RANIN J, JEVTOVIC D. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IRIS AFTER INITIATION OF HAART: CASE REPORT. INT J INFECT DIS. 2015;NOV 18",28,YR,,M,Y,,,20170417,,OT,RS,RS,Efavirenz,Drug resistance;Immune reconstitution inflammatory syndrome,118259283,HO,,,,,,,,,118259283,1,HIV infection
11883063,118830634,4,F,,20170608,20151231,20170612,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090408,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20170612,,OT,PT,PT,EFAVIRENZ,Caesarean section;Drug use disorder;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,118830634,OT,,,118830634,1,2007,,,,118830634,1,HIV infection
12145960,121459602,2,F,20130123,20170609,20160304,20170616,EXP,,FR-VIIV HEALTHCARE LIMITED-B0871259A,VIIV,,44,YR,,M,Y,57,KG,20170616,,MD,FR,FR,SUSTIVA,Acute coronary syndrome;Hypovolaemia,121459602,HO,,,121459602,1,20121002,,,,121459602,1,HIV infection
12253502,122535022,2,F,,20160405,20160411,20170620,EXP,,US-GILEAD-2016-0207534,GILEAD,,,,,F,Y,,,20170620,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy,,,,,122535022,1,20160202,20160201,,,122535022,1,HIV infection
12256592,122565922,2,F,,20170621,20160412,20170621,EXP,,US-VIIV HEALTHCARE LIMITED-US2016048464,VIIV,,,,,F,Y,,,20170621,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy,,,,,122565922,1,20160202,20160201,,,122565922,1,HIV infection
12256882,122568822,2,F,,20170621,20160412,20170621,EXP,,US-GLAXOSMITHKLINE-US2016048464,GLAXOSMITHKLINE,,,,,F,Y,,,20170621,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy,,,,,122568822,1,20160202,20160201,,,122568822,1,HIV infection
12308286,123082865,5,F,20160202,20170328,20160426,20170404,EXP,,UG-GILEAD-2016-0210345,GILEAD,,56,YR,A,F,Y,65,KG,20170404,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Radius fracture;Ulna fracture,123082865,HO,,,123082865,1,20150709,,,,123082865,1,HIV infection
12383446,123834464,4,F,,20170608,20160518,20170619,EXP,,FR-BMSGILMSD-2016-0214004,GILEAD,,58,YR,A,M,Y,,,20170619,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporotic fracture;Renal tubular disorder,123834464,OT,,,123834464,1,2006,,,,123834464,1,HIV infection
12502978,125029783,3,F,20040806,20170526,20160628,20170602,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13454525,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,,,20170602,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Hepatic function abnormal;Hypercholesterolaemia;Hypertriglyceridaemia;Lipoatrophy,125029783,OT,,,125029783,1,20030304,20050304,,,125029783,1,HIV infection
12563472,125634724,4,F,20000322,20170426,20160715,20170504,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0617,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20170504,,MD,JP,JP,EFAVIRENZ,Hepatic cirrhosis;Hypertriglyceridaemia;Pancytopenia,125634724,OT,,,125634724,1,19990819,20040331,,,125634724,1,HIV infection
12567182,125671826,6,F,20160603,20170511,20160718,20170516,EXP,,FR-GILEAD-2016-0223323,GILEAD,,33,YR,A,M,Y,68,KG,20170516,,CN,FR,FR,EFAVIRENZ;SUSTIVA,Acute kidney injury;Atrial flutter;Cardiac failure;Hepatocellular injury;Myocarditis;Renal impairment;Transplant rejection,125671826,HO,,,125671826,1,20160405,20160628,,,125671826,1,Chronic hepatitis C
12642922,126429225,5,F,,20170424,20160811,20170503,EXP,,US-CIPLA LTD.-2016US17002,CIPLA,,,,,,Y,,,20170503,,OT,US,US,Efavirenz,Acute kidney injury;Drug interaction;Fall;Nephropathy toxic,126429225,OT,,,,,,,,,126429225,1,HIV infection
12687626,126876267,7,F,20160802,20170328,20160825,20170405,EXP,,UG-GILEAD-2016-0227055,GILEAD,,37,YR,A,M,Y,49,KG,20170405,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia,126876267,DE,,,126876267,1,20140319,20160801,,,126876267,1,Kaposi's sarcoma AIDS related
12689480,126894803,3,F,20140810,20170419,20160826,20170421,EXP,,IT-GLAXOSMITHKLINE-IT2016123953,GLAXOSMITHKLINE,,51,YR,,F,Y,48,KG,20170421,,OT,IT,IT,EFAVIRENZ,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,126894803,OT,,,126894803,1,20120627,20141110,,,126894803,1,HIV infection
12689614,126896144,4,F,20140810,20170419,20160826,20170421,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016123953,VIIV,,51,YR,,F,Y,48,KG,20170421,,OT,IT,IT,EFAVIRENZ,Depression;Diabetes mellitus;Foot fracture;Hypercholesterolaemia;Hypertension;Insomnia;Nightmare;Osteoporosis;Vitamin D deficiency,126896144,OT,,,126896144,1,20120627,20141110,,,126896144,1,HIV infection
12876845,128768454,4,F,201004,20170601,20161024,20170605,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2016JPN152007,VIIV,,49,YR,,F,Y,,,20170605,,CN,JP,JP,EFAVIRENZ,Chronic kidney disease;Diabetes mellitus;Hypertension;Lipids abnormal,128768454,OT,,,128768454,1,2009,20150202,,,128768454,1,HIV infection
12876972,128769724,4,F,201004,20170601,20161024,20170605,EXP,,JP-GLAXOSMITHKLINE-JP2016JPN152007,GLAXOSMITHKLINE,,49,YR,,F,Y,,,20170605,,CN,JP,JP,EFAVIRENZ,Chronic kidney disease;Diabetes mellitus;Hypertension;Lipids abnormal,128769724,OT,,,128769724,1,2009,20150202,,,128769724,1,HIV infection
12953145,129531454,4,F,20160510,20170620,20161117,20170628,EXP,,BR-ABBVIE-16P-020-1783211-00,ABBVIE,,33,YR,,M,Y,70,KG,20170628,,CN,BR,BR,EFAVIRENZ,Abasia;Asthenia;CD4 lymphocytes decreased;Crying;Decreased appetite;Eating disorder;Fatigue;Immunodeficiency;Memory impairment;Nodule;Somnolence;Viral load increased;Visual impairment,129531454,OT,,,129531454,1,2012,2014,,,129531454,1,Acquired immunodeficiency syndrome
12985056,129850562,2,F,,20170323,20161129,20170407,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20170407,,OT,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,129850562,OT,,,,,,,,,129850562,1,HIV infection
13060218,130602183,3,F,,20170509,20161223,20170512,EXP,,US-GILEAD-2016-0250332,GILEAD,,,,N,F,Y,,,20170512,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Atrial septal defect;Cardiac aneurysm;Exposure to communicable disease;Foetal exposure during pregnancy;Poor feeding infant;Small for dates baby;Toxoplasmosis,130602183,CA,,,,,,,,,130602183,1,HIV infection
13060255,130602552,2,F,,20170412,20161223,20170420,EXP,,US-GILEAD-2016-0250167,GILEAD,,,,N,M,Y,,,20170420,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diaphragmatic hernia;Foetal exposure during pregnancy;Otitis media;Pleural effusion,130602552,CA,,,130602552,1,20071205,2007,,,130602552,1,HIV infection
13062170,130621702,2,F,,20170518,20161226,20170524,EXP,,US-GILEAD-2016-0250336,GILEAD,,,,N,F,Y,,,20170524,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cataract;Foetal exposure during pregnancy;Laryngomalacia;Stridor,130621702,OT,,,,,,,,,130621702,1,HIV test positive
13106609,131066092,2,F,20140715,20170105,20170111,20170623,EXP,,UG-GILEAD-2017-0252401,GILEAD,,28,YR,A,F,Y,,,20170623,,OT,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,131066092,OT,,,131066092,1,20140620,20140619,,,131066092,1,HIV infection
13196502,131965029,9,F,20170201,20170529,20170208,20170602,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK015761,VIIV,,0,DY,,F,Y,1.89,KG,20170602,,MD,BR,BR,Efavirenz,Atrial septal defect;Congenital cytomegalovirus infection,131965029,LT,,,131965029,1,20161223,20170201,,,131965029,1,HIV infection
13205319,132053194,4,F,20170123,20170412,20170208,20170420,EXP,,PE-GILEAD-2017-0257015,GILEAD,,29,YR,A,M,Y,60.5,KG,20170420,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Suicidal ideation,132053194,OT,,,132053194,1,20140411,20161230,,,132053194,1,HIV infection
13220172,132201723,3,F,20170201,20170609,20170210,20170615,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-011279,BRISTOL MYERS SQUIBB,,15,YR,,F,Y,,,20170615,,OT,BR,BR,EFAVIRENZ,Maternal exposure during pregnancy;Premature delivery,132201723,OT,,,132201723,1,20161223,20170201,,,132201723,1,HIV infection
13265550,132655502,2,F,,20170404,20170223,20170407,EXP,,ES-JNJFOC-20170209920,JANSSEN,,,,,,Y,,,20170407,,MD,ES,ES,EFAVIRENZ,Bacterial sepsis;Diarrhoea;Drug interaction;Neurotoxicity;Renal colic;Treatment noncompliance;Virologic failure,132655502,OT,,,,,,,,,132655502,1,HIV infection
13343513,133435133,3,F,20161202,20170410,20170316,20170418,EXP,,CM-GILEAD-2017-0262397,GILEAD,,64,YR,,M,Y,86,KG,20170418,,OT,CM,CM,TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Hypertension,133435133,OT,,,133435133,1,20161108,20170131,,,133435133,1,Hepatitis C
13343560,133435603,3,F,20161122,20170327,20170316,20170404,EXP,,CM-GILEAD-2017-0262398,GILEAD,,55,YR,A,F,Y,66,KG,20170404,,OT,CM,CM,TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Hypertension,133435603,OT,,,133435603,1,20161108,20170131,,,133435603,1,Hepatitis C
13366442,133664423,3,F,20110822,20170331,20170323,20170405,EXP,,GR-GILEAD-2017-0263312,GILEAD,,34,YR,A,M,Y,87,KG,20170405,,MD,GR,GR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,133664423,OT,,,133664423,1,200804,201109,,,133664423,1,HIV infection
13368013,133680132,2,F,2016,20170320,20170324,20170403,EXP,,BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-136605,RANBAXY,,,,,M,Y,,,20170403,,CN,US,BR,Lamivudine/Efavirenz/Tenofovir,Congenital naevus;Foetal exposure during pregnancy,133680132,OT,,,133680132,1,20170302,20170302,,,133680132,1,Product used for unknown indication
13368017,133680172,2,F,2016,20170320,20170324,20170403,EXP,,BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-136604,RANBAXY,,22,YR,,F,Y,,,20170403,,CN,US,BR,Lamivudine/Efavirenz/Tenofovir,Exposure during pregnancy;Live birth,133680172,OT,,,133680172,3,20170302,20170302,,,133680172,1,Product used for unknown indication
13379518,133795184,4,F,20160515,20170421,20170328,20170426,EXP,,AR-GILEAD-2017-0263863,GILEAD,,36,YR,A,M,Y,68,KG,20170426,,MD,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional overdose;Suicide attempt,133795184,LT,,,133795184,1,20150723,,,,133795184,1,HIV infection
13382748,133827482,2,F,19990929,20170329,20170329,20170405,EXP,,AU-ABBVIE-17P-008-1919042-00,ABBVIE,,43,YR,,M,Y,71,KG,20170405,,CN,AU,AU,EFAVIRENZ,Acute kidney injury;Hydroureter;Nephrolithiasis;Ureterolithiasis,133827482,OT,,,133827482,1,19990429,19990929,,,133827482,1,HIV infection
13384057,133840572,2,F,20170315,20170407,20170329,20170413,EXP,,BR-GILEAD-2017-0264275,GILEAD,,,,,,Y,,,20170413,,OT,BR,BR,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Pyelocaliectasis,133840572,OT,,,133840572,2,20170317,,,,133840572,1,HIV infection
13395440,133954401,1,I,,20170327,20170403,20170403,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-026458,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170403,,CN,US,US,SUSTIVA,Gastric disorder,,,,,,,,,,,133954401,1,HIV infection
13396102,133961021,1,I,,20170327,20170403,20170403,EXP,,DK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-028172,BRISTOL MYERS SQUIBB,,64,YR,,M,Y,,,20170403,,CN,DK,DK,EFAVIRENZ,Myocardial ischaemia;Osteoporosis;Renal disorder,133961021,OT,,,,,,,,,133961021,1,Product used for unknown indication
13399265,133992651,1,I,,20170321,20170404,20170404,EXP,,BR-HETERO LABS LTD-1064955,HETERO,,,,,M,Y,,,20170404,,OT,BR,BR,Efavirenz,Congenital syphilis;Foetal exposure during pregnancy,133992651,CA,,,,,,,,,133992651,1,HIV infection
13400686,134006861,1,I,,20170328,20170404,20170404,EXP,,US-ASTELLAS-2017US012531,ASTELLAS,,,,,,Y,,,20170404,,OT,US,US,EFAVIRENZ,Drug level below therapeutic;Toxicity to various agents,134006861,OT,,,,,,,,,134006861,1,Renal transplant
13401350,134013501,1,I,,20170328,20170404,20170404,EXP,,ET-GILEAD-2017-0265558,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170404,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134013501,OT,,,,,,,,,134013501,1,HIV infection
13401353,134013531,1,I,20150610,20170313,20170404,20170404,EXP,,IN-GILEAD-2017-0262826,GILEAD,"KUMAR A, MAJHEE L, GARI M. CAUSALITY, SEVERITY AND PREVENTABILITY ASSESSMENT OF ADVERSE DRUG REACTIONS IN PATIENTS RECEIVED ANTI-RETROVIRAL THERAPY IN A TERTIARY CARE HOSPITAL: A RETROSPECTIVE STUDY.. NATIONAL JOURNAL OF PHYSIOLOGY, PHARMACY AND PHARMACOLOGY.. 2017;7(2):PP 178-182",32,YR,A,F,Y,24,KG,20170404,,MD,IN,IN,EFAVIRENZ,Renal failure,134013531,HO,,,134013531,1,201411,,,,134013531,1,HIV infection
13402416,134024164,4,F,20170317,20170419,20170404,20170428,EXP,,MW-GILEAD-2017-0264667,GILEAD,,51,YR,A,M,Y,,,20170428,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaria;Neutropenia;Pneumonia bacterial;Renal failure,134024164,OT,,,134024164,1,20160816,20170312,,,134024164,1,Acquired immunodeficiency syndrome
13402471,134024711,1,I,,20170328,20170404,20170404,EXP,,ET-GILEAD-2017-0265777,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170404,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134024711,OT,,,,,,,,,134024711,1,HIV infection
13404987,134049871,1,I,,20170328,20170405,20170405,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017047999,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134049871,OT,,,,,,,,,134049871,1,HIV infection
13404994,134049941,1,I,20170323,20170404,20170405,20170405,EXP,GB-MHRA-EYC 00156013,GB-VIIV HEALTHCARE LIMITED-GB2017047846,VIIV,,45,YR,,F,Y,,,20170405,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134049941,OT,,,134049941,1,20170313,20170323,,,134049941,1,HIV infection
13404997,134049971,1,I,,20170328,20170405,20170405,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017047944,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134049971,OT,,,,,,,,,134049971,1,HIV infection
13405115,134051151,1,I,,20170328,20170405,20170405,EXP,,ET-GLAXOSMITHKLINE-ET2017047999,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134051151,OT,,,,,,,,,134051151,1,HIV infection
13405121,134051211,1,I,,20170328,20170405,20170405,EXP,,ET-GLAXOSMITHKLINE-ET2017047944,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134051211,OT,,,,,,,,,134051211,1,HIV infection
13405315,134053151,1,I,20170323,20170404,20170405,20170405,EXP,GB-MHRA-EYC 00156013,GB-GLAXOSMITHKLINE-GB2017047846,GLAXOSMITHKLINE,,45,YR,,F,Y,,,20170405,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134053151,OT,,,134053151,1,20170313,20170323,,,134053151,1,HIV infection
13407143,134071431,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265778,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134071431,OT,,,,,,,,,134071431,1,HIV infection
13407151,134071511,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265779,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134071511,OT,,,,,,,,,134071511,1,HIV infection
13407200,134072002,2,F,,20170419,20170405,20170426,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-029435,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170426,,OT,US,US,SUSTIVA,Incorrect product storage,,,,,,,,,,,134072002,1,Product used for unknown indication
13407354,134073541,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265780,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073541,OT,,,,,,,,,134073541,1,HIV infection
13407355,134073551,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265781,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073551,OT,,,,,,,,,134073551,1,HIV infection
13407356,134073561,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265782,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073561,OT,,,,,,,,,134073561,1,HIV infection
13407357,134073571,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265783,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073571,OT,,,,,,,,,134073571,1,HIV infection
13407358,134073581,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265784,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073581,OT,,,,,,,,,134073581,1,HIV infection
13407362,134073621,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265785,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073621,OT,,,,,,,,,134073621,1,HIV infection
13407365,134073651,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265787,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073651,OT,,,,,,,,,134073651,1,HIV infection
13407367,134073671,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265786,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073671,OT,,,,,,,,,134073671,1,HIV infection
13407374,134073741,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265788,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073741,OT,,,,,,,,,134073741,1,HIV infection
13407375,134073751,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265789,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073751,OT,,,,,,,,,134073751,1,HIV infection
13407395,134073951,1,I,,20170328,20170405,20170405,EXP,,ET-GILEAD-2017-0265790,GILEAD,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170405,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134073951,OT,,,,,,,,,134073951,1,HIV infection
13413107,134131072,2,F,,20170328,20170406,20170406,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048814,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170406,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134131072,OT,,,,,,,,,134131072,1,HIV infection
13414642,134146422,2,F,,20170328,20170406,20170406,EXP,,ET-GLAXOSMITHKLINE-ET2017048814,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170406,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134146422,OT,,,,,,,,,134146422,1,HIV infection
13415974,134159742,2,F,,20170406,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048863,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159742,OT,,,,,,,,,134159742,1,HIV infection
13415976,134159762,2,F,,20170406,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048857,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159762,OT,,,,,,,,,134159762,1,HIV infection
13415978,134159782,2,F,,20170406,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048862,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159782,OT,,,,,,,,,134159782,1,HIV infection
13415979,134159792,2,F,,20170406,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048868,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159792,OT,,,,,,,,,134159792,1,HIV infection
13415980,134159802,2,F,,20170406,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048865,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159802,OT,,,,,,,,,134159802,1,HIV infection
13415987,134159872,2,F,,20170406,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048864,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159872,OT,,,,,,,,,134159872,1,HIV infection
13415992,134159922,2,F,,20170406,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048858,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159922,OT,,,,,,,,,134159922,1,HIV infection
13415997,134159972,2,F,,20170406,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048870,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134159972,OT,,,,,,,,,134159972,1,HIV infection
13416000,134160002,2,F,,20170406,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048816,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160002,OT,,,,,,,,,134160002,1,HIV infection
13416005,134160052,2,F,,20170406,20170406,20170411,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048867,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160052,OT,,,,,,,,,134160052,1,HIV infection
13416008,134160082,2,F,,20170406,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048860,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160082,OT,,,,,,,,,134160082,1,HIV infection
13416010,134160102,2,F,,20170406,20170406,20170410,EXP,,ET-VIIV HEALTHCARE LIMITED-ET2017048861,VIIV,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134160102,OT,,,,,,,,,134160102,1,HIV infection
13417093,134170932,2,F,,20170406,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048863,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134170932,OT,,,,,,,,,134170932,1,HIV infection
13417095,134170952,2,F,,20170406,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048857,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134170952,OT,,,,,,,,,134170952,1,HIV infection
13417097,134170972,2,F,,20170406,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048862,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134170972,OT,,,,,,,,,134170972,1,HIV infection
13417100,134171002,2,F,,20170406,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048868,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171002,OT,,,,,,,,,134171002,1,HIV infection
13417103,134171032,2,F,,20170406,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048865,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171032,OT,,,,,,,,,134171032,1,HIV infection
13417116,134171162,2,F,,20170406,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048864,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171162,OT,,,,,,,,,134171162,1,HIV infection
13417126,134171262,2,F,,20170406,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048858,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171262,OT,,,,,,,,,134171262,1,HIV infection
13417136,134171362,2,F,,20170406,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048870,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171362,OT,,,,,,,,,134171362,1,HIV infection
13417139,134171392,2,F,,20170406,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048816,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171392,OT,,,,,,,,,134171392,1,HIV infection
13417142,134171422,2,F,,20170406,20170406,20170411,EXP,,ET-GLAXOSMITHKLINE-ET2017048867,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170411,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171422,OT,,,,,,,,,134171422,1,HIV infection
13417145,134171452,2,F,,20170406,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048860,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E.. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS.. FRONTIERS IN PHARMACOLOGY.. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171452,OT,,,,,,,,,134171452,1,HIV infection
13417148,134171482,2,F,,20170406,20170406,20170410,EXP,,ET-GLAXOSMITHKLINE-ET2017048861,GLAXOSMITHKLINE,PETROS Z. KISHIKAWA J. MAKONNEN E. YIMER G. HABTEWOLD A. AKLILLU E... HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONTIERS IN PHARMACOLOGY. 2017;8:NI,,,A,,Y,,,20170410,,MD,ET,ET,EFAVIRENZ,Drug-induced liver injury,134171482,OT,,,,,,,,,134171482,1,HIV infection
13417539,134175391,1,I,,20170316,20170406,20170406,EXP,,GB-GLAXOSMITHKLINE-GB2017GSK038125,GLAXOSMITHKLINE,,63,YR,,M,Y,,,20170406,,CN,GB,GB,EFAVIRENZ,CD4 lymphocytes decreased;Condition aggravated;Depression;Diarrhoea;Feeling abnormal;Haemochromatosis trait;Hepatic function abnormal;Lipodystrophy acquired;Nausea;Rash;Renal impairment;Vomiting;Weight decreased,134175391,OT,,,,,,,,,134175391,1,HIV infection
13417590,134175901,1,I,,20170316,20170406,20170406,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017GSK038125,VIIV,,63,YR,,M,Y,,,20170406,,CN,GB,GB,EFAVIRENZ,CD4 lymphocytes decreased;Condition aggravated;Depression;Diarrhoea;Feeling abnormal;Haemochromatosis trait;Hepatic function abnormal;Lipodystrophy acquired;Nausea;Rash;Renal impairment;Vomiting;Weight decreased,134175901,OT,,,,,,,,,134175901,1,HIV infection
13417675,134176753,3,F,,20170329,20170407,20170618,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-030315,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20170618,,OT,GB,GB,EFAVIRENZ,Blood HIV RNA increased;Drug resistance;Viral mutation identified,134176753,OT,,,,,,,,,134176753,1,HIV infection
13419456,134194561,1,I,,20170329,20170407,20170407,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-028573,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170407,,OT,US,US,EFAVIRENZ,Drug level below therapeutic;Labelled drug-drug interaction medication error;Transplant failure,134194561,OT,,,,,,,,,134194561,1,HIV infection
13419458,134194581,1,I,,20170329,20170407,20170407,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-030281,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170407,,OT,US,US,EFAVIRENZ,Drug level below therapeutic;Labelled drug-drug interaction medication error;Transplant failure,134194581,OT,,,,,,,,,134194581,1,HIV infection
13421039,134210391,1,I,,20170404,20170410,20170410,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-029323,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170410,,CN,US,US,SUSTIVA,Deafness,134210391,OT,,,,,,,,,134210391,1,Product used for unknown indication
13423892,134238921,1,I,20170323,20170404,20170410,20170410,EXP,GB-MHRA-EYC 00156013,GB-MYLANLABS-2017M1021644,MYLAN,,,,,,Y,,,20170408,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134238921,OT,,,134238921,1,20170313,20170323,,,134238921,1,HIV infection
13425309,134253091,1,I,20060110,20061221,20170411,20170411,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13623434,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20170411,,CN,US,JP,EFAVIRENZ,Depression;Disseminated intravascular coagulation;Disseminated tuberculosis;Kaposi's sarcoma,134253091,DE,,,134253091,1,20060111,20060130,,,134253091,1,HIV infection
13426574,134265741,1,I,,20170328,20170411,20170411,EXP,,ZA-SUN PHARMACEUTICAL INDUSTRIES LTD-2017R1-137819,RANBAXY,,37,YR,,F,Y,,,20170411,,OT,GB,ZA,"Efavirenz, emtricitabine, tenofovir",Condition aggravated;Drug ineffective;Tuberculosis,134265741,OT,,,134265741,5,201407,201507,,,134265741,1,Tuberculosis
13426660,134266601,1,I,,20170221,20170411,20170411,PER,,AR-LUPIN PHARMACEUTICALS INC.-2017-00903,LUPIN,,49,YR,,F,Y,,,20170411,,MD,AR,AR,EFAVIRENZ,Drug interaction;Viral load increased,,,,,134266601,1,2001,2007,,,134266601,1,HIV infection
13426671,134266711,1,I,,20170221,20170411,20170411,PER,,AR-LUPIN PHARMACEUTICALS INC.-2017-00905,LUPIN,,75,YR,,M,Y,,,20170411,,MD,AR,AR,EFAVIRENZ;EMTRICITABINE/TENOFOVIR/EFAVIRENZ,Drug interaction;Viral load increased,,,,,134266711,1,2004,,,,134266711,1,HIV infection
13427003,134270031,1,I,,20170328,20170411,20170411,EXP,ZA-MLMSERVICE-20170322-0654207-1,ZA-ALKEM LABORATORIES LIMITED-ZA-ALKEM-2017-00137,ALKEM,,37,YR,,F,Y,,,20170411,,CN,GB,ZA,"EFAVIRENZ, EMTRICITABINE, TENOFOVIR",Condition aggravated;Drug ineffective;Tuberculosis,134270031,OT,,,134270031,7,201408,201507,,,134270031,1,Tuberculosis
13427528,134275282,2,F,,20170414,20170411,20170424,EXP,,GB-GLAXOSMITHKLINE-GB2017GSK048490,GLAXOSMITHKLINE,,,,,M,Y,,,20170424,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident,134275282,OT,,,,,,,,,134275282,1,Product used for unknown indication
13427593,134275932,2,F,,20170414,20170411,20170424,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017GSK048490,VIIV,,,,,M,Y,,,20170424,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident,134275932,OT,,,,,,,,,134275932,1,Product used for unknown indication
13433250,134332502,2,F,20160919,20170424,20170412,20170501,EXP,,CH-GILEAD-2017-0266937,GILEAD,,71,YR,E,M,Y,,,20170501,,OT,CH,CH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Osteoporosis;Renal tubular dysfunction,134332502,OT,,,134332502,1,200805,,,,134332502,1,HIV infection
13433605,134336051,1,I,,20170330,20170412,20170412,EXP,,GB-MYLANLABS-2017M1021751,MYLAN,,,,,,Y,,,20170412,,CN,GB,GB,Efavirenz Tablets 600mg,Cerebrovascular accident,134336051,OT,,,,,,,,,134336051,1,Product used for unknown indication
13440630,134406301,1,I,,20170328,20170413,20170413,EXP,,MX-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-031752,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170413,,CN,MX,MX,EFAVIRENZ,Pneumonia,134406301,OT,,,134406301,1,,201609,,,134406301,1,Product used for unknown indication
13441289,134412891,1,I,20170121,20170406,20170413,20170413,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-030701,BRISTOL MYERS SQUIBB,,65,YR,,M,Y,,,20170413,,OT,CN,CN,EFAVIRENZ,Liver injury,134412891,HO,,,134412891,1,20141028,20170121,,,134412891,1,Viral infection
13443187,134431871,1,I,,20170330,20170414,20170414,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-031493,BRISTOL MYERS SQUIBB,,53,YR,,M,Y,,,20170414,,OT,US,US,EFAVIRENZ,Alanine aminotransferase increased,134431871,OT,,,,,,,,,134431871,1,Acquired immunodeficiency syndrome
13443499,134434991,1,I,,20170330,20170414,20170414,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-032496,BRISTOL MYERS SQUIBB,,51,YR,,M,Y,,,20170414,,OT,US,US,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Neutropenia;Renal failure,134434991,OT,,,,,,,,,134434991,1,Acquired immunodeficiency syndrome
13443501,134435011,1,I,,20170330,20170414,20170414,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-032495,BRISTOL MYERS SQUIBB,,65,YR,,M,Y,,,20170414,,OT,US,US,EFAVIRENZ,Herpes zoster;Neutropenia,134435011,OT,,,,,,,,,134435011,1,Acquired immunodeficiency syndrome
13444431,134444312,2,F,20170227,20170425,20170414,20170502,EXP,,GB-GILEAD-2017-0262235,GILEAD,,51,YR,A,M,Y,78.2,KG,20170502,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ankle fracture,134444312,DS,,,134444312,1,20121030,,,,134444312,1,HIV infection
13445335,134453352,2,F,20170213,20170428,20170414,20170503,EXP,,ZA-GILEAD-2017-0261904,GILEAD,,49,YR,A,F,Y,89.4,KG,20170503,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Demyelination,134453352,HO,,,134453352,1,20150709,,,,134453352,1,HIV infection
13446147,134461471,1,I,,20170403,20170417,20170417,EXP,,UG-ROCHE-1917217,ROCHE,"KIGUBA R, KARAMAGI C AND BIRD S. ANTIBIOTIC-ASSOCIATED SUSPECTED ADVERSE DRUG REACTIONS AMONG HOSPITALIZED PATIENTS IN UGANDA: A PROSPECTIVE COHORT STUDY . PHARMACOLOGY RESEARCH AND PERSPECTIVES 2017 APR 01;5 (2):1-16.",,,A,,Y,,,20170417,,OT,UG,UG,EFAVIRENZ,Abdominal pain;Anaemia;Decreased appetite;Diarrhoea;Dizziness;Drug interaction;Jaundice;Paraesthesia;Pyrexia;Stomatitis;Vomiting,134461471,HO,,,,,,,,,134461471,1,Product used for unknown indication
13446778,134467781,1,I,20170323,20170404,20170417,20170417,EXP,GB-MHRA-EYC 00156013,GB-TEVA-758083ACC,TEVA,,45,YR,,F,Y,,,20170417,,PH,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134467781,OT,,,134467781,1,20170313,20170323,,,134467781,1,HIV infection
13449088,134490882,2,F,20170203,20170518,20170417,20170525,EXP,,FR-GILEAD-2017-0267012,GILEAD,,53,YR,A,M,Y,68,KG,20170525,,MD,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal stoma complication,134490882,HO,,,134490882,1,20101105,,,,134490882,1,HIV infection
13450558,134505581,1,I,20170323,20170404,20170418,20170418,EXP,GB-MHRA-ADR 23922700,GB-LUPIN PHARMACEUTICALS INC.-2017-01766,LUPIN,,45,YR,,F,Y,,,20170418,,CN,GB,GB,EFAVIRENZ,Erythema;Lip swelling;Pruritus;Rash papular,134505581,OT,,,134505581,1,20170313,20170323,,,134505581,1,HIV infection
13456460,134564604,4,F,20170203,20170524,20170418,20170531,EXP,,UG-GILEAD-2017-0267324,GILEAD,,56,YR,A,F,Y,83,KG,20170531,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Transient ischaemic attack,134564604,HO,,,134564604,1,20150608,,,,134564604,1,HIV infection
13457787,134577871,1,I,19990929,20170411,20170419,20170419,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-032516,BRISTOL MYERS SQUIBB,,43,YR,,M,Y,71,KG,20170419,,CN,AU,AU,EFAVIRENZ,Acute kidney injury;Hydroureter;Nephrolithiasis,134577871,OT,,,134577871,1,19990429,19990927,,,134577871,1,HIV infection
13458871,134588711,1,I,,20170407,20170419,20170419,EXP,,"CN-LANNETT COMPANY, INC.-PK-2017LAN000724",LANNETT,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI. 2016;32(6):1574-1579",27,YR,,M,Y,,,20170419,,MD,CN,PK,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,134588711,OT,,,,,,,,,134588711,1,Acquired immunodeficiency syndrome
13461110,134611101,1,I,,20170418,20170420,20170420,EXP,,BR-STRIDES ARCOLAB LIMITED-2017SP006568,STRIDES,,,,,,Y,,,20170420,,OT,BR,BR,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F,Congenital naevus;Foetal exposure during pregnancy,134611101,CA,,,134611101,2,20170327,20170327,,,134611101,1,Product used for unknown indication
13461441,134614411,1,I,,20170419,20170420,20170420,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2017056869,VIIV,,,,,M,Y,,,20170420,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident,134614411,OT,,,,,,,,,134614411,1,Product used for unknown indication
13461442,134614421,1,I,,20170411,20170420,20170420,EXP,,US-VIIV HEALTHCARE LIMITED-US2017GSK055892,VIIV,"JOHNSTON C, HARRINGTON R, JAIN R, SCHIFFER J, KIEM H-P, WOOLFREY A. SAFETY AND EFFICACY OF COMBINATION ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUSEINFECTED ADULTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016;22:149-156",43,YR,,M,Y,,,20170420,,OT,US,US,EFAVIRENZ,Acute kidney injury;Pneumonia influenzal;Skin toxicity;Toxicity to various agents,134614421,OT,,,,,,,,,134614421,1,HIV infection
13461447,134614471,1,I,,20170411,20170420,20170420,EXP,,US-VIIV HEALTHCARE LIMITED-US2017GSK055894,VIIV,"JOHNSTON C, HARRINGTON R, JAIN R, SCHIFFER J, KIEM H-P, WOOLFREY A. SAFETY AND EFFICACY OF COMBINATION ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUSEINFECTED ADULTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 2016;22:149-156",60,YR,,M,Y,,,20170420,,OT,US,US,EFAVIRENZ,Cytomegalovirus infection;Malabsorption,134614471,OT,,,,,,,,,134614471,1,Stem cell transplant
13461746,134617461,1,I,,20170419,20170420,20170420,EXP,,GB-GLAXOSMITHKLINE-GB2017056869,GLAXOSMITHKLINE,,,,,M,Y,,,20170420,,CN,GB,GB,EFAVIRENZ,Cerebrovascular accident,134617461,OT,,,,,,,,,134617461,1,Product used for unknown indication
13462364,134623641,1,I,,20170407,20170420,20170420,EXP,,"CN-LANNETT COMPANY, INC.-PK-2017LAN000721",LANNETT,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI. 2016;32(6):1574-1579",28,YR,,M,Y,,,20170420,,MD,CN,PK,EFAVIRENZ,Bone marrow failure;Gastrointestinal disorder,134623641,LT,,,,,,,,,134623641,1,Acquired immunodeficiency syndrome
13462367,134623671,1,I,,20170407,20170420,20170420,EXP,,"CN-LANNETT COMPANY, INC.-PK-2017LAN000720",LANNETT,"ZUO S, XU N, LI Z, LI N, XIA H, REN H, ET AL.. CLINICAL ANALYSIS OF FIVE CASES OF AIDS-RELATED NON-HODGKIN LYMPHOMA. PAK-J-MED-SCI. 2016;32(6):1574-1579",28,YR,,M,Y,,,20170420,,MD,CN,PK,EFAVIRENZ,Acinetobacter infection;Bone marrow failure;Gastrointestinal disorder;Respiratory failure,134623671,LT,,,,,,,,,134623671,1,Acquired immunodeficiency syndrome
13462596,134625963,3,F,20160309,20170622,20170420,20170629,EXP,,UG-GILEAD-2017-0267647,GILEAD,,30,YR,A,F,Y,53,KG,20170629,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal death;Maternal exposure during pregnancy,134625963,OT,,,134625963,1,20150922,20160920,,,134625963,1,HIV infection
13462608,134626082,2,F,20170306,20170518,20170420,20170523,EXP,,UG-GILEAD-2017-0268455,GILEAD,,32,YR,A,F,Y,53,KG,20170523,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion threatened;Maternal exposure during pregnancy,134626082,HO,,,134626082,1,20150922,20160920,,,134626082,1,HIV infection
13462645,134626451,1,I,,20170412,20170420,20170420,EXP,,US-GILEAD-2017-0268443,GILEAD,,,,,F,Y,123,KG,20170420,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Maternal exposure during pregnancy;Premature labour;Twin pregnancy,134626451,DE,,,134626451,1,,2007,,,134626451,1,HIV infection
13463867,134638672,2,F,20170115,20170622,20170420,20170629,EXP,,UG-GILEAD-2017-0268451,GILEAD,,32,YR,A,F,Y,53,KG,20170629,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion threatened;Maternal exposure before pregnancy,134638672,OT,,,134638672,1,20150922,20160920,,,134638672,1,HIV infection
13466716,134667163,3,F,20170326,20170502,20170421,20170505,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK057369,VIIV,,0,DY,,M,Y,3.29,KG,20170505,,MD,BR,BR,Efavirenz,Tricuspid valve incompetence,134667163,CA,,,134667163,1,20161118,20170325,,,134667163,1,HIV infection
13468632,134686322,2,F,,20170419,20170421,20170426,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-033888,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170426,,CN,GB,GB,SUSTIVA,Cerebrovascular accident,134686322,OT,,,,,,,,,134686322,1,Product used for unknown indication
13469134,134691341,1,I,19990929,20170411,20170421,20170421,EXP,,AU-009507513-1704AUS008412,MERCK,,43,YR,,M,Y,71,KG,20170421,,OT,AU,AU,EFAVIRENZ,Acute kidney injury;Hydroureter;Nephrolithiasis,134691341,OT,,,134691341,1,19990429,19990929,,,134691341,1,HIV infection
13473674,134736743,3,F,201704,20170512,20170424,20170516,EXP,,US-VIFOR (INTERNATIONAL) INC.-VIT-2017-04377,VIFOR,,65,YR,,M,Y,,,20170516,,OT,US,US,SUSTIVA,Dialysis;Product quality issue;Product taste abnormal,134736743,OT,,,134736743,1,20170405,,,,134736743,1,Hyperkalaemia
13480067,134800673,3,F,20170320,20170517,20170425,20170522,EXP,,UG-GILEAD-2017-0269067,GILEAD,,51,YR,A,F,Y,51,KG,20170522,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Tumour haemorrhage,134800673,HO,,,134800673,1,20131022,,,,134800673,1,HIV infection
13484210,134842103,3,F,,20170413,20170425,20170426,EXP,,BR-CIPLA LTD.-2017BR07215,CIPLA,,,,,,Y,,,20170426,,OT,BR,BR,Lamivudine/Efavirenz/Tenofovir,Congenital naevus;Foetal exposure during pregnancy,134842103,CA,,,,,,,,,,,
13484464,134844646,6,F,201701,20170609,20170425,20170615,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-034926,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,,,20170615,,MD,BR,BR,EFAVIRENZ,Bacterial vaginosis;Caesarean section;Genital herpes;Live birth;Maternal exposure during pregnancy;Urinary tract infection,134844646,OT,,,134844646,1,20161118,20170325,,,134844646,1,HIV infection
13490238,134902382,2,F,2017,20170627,20170426,20170630,EXP,,BR-ASTRAZENECA-2017SE42683,ASTRAZENECA,,,,,M,Y,,,20170630,,CN,BR,BR,EFAVIRENZ,Dehydration;Ischaemic stroke,134902382,OT,,,134902382,1,2017,2017,,,134902382,2,Acquired immunodeficiency syndrome
13490580,134905801,1,I,,20170417,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025314,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134905801,OT,,,,,,,,,134905801,1,HIV infection
13491974,134919741,1,I,,20170417,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025354,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134919741,OT,,,,,,,,,134919741,1,HIV infection
13491975,134919751,1,I,,20170417,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025355,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134919751,OT,,,,,,,,,134919751,1,HIV infection
13492393,134923931,1,I,,20170417,20170427,20170427,EXP,,GB-MYLANLABS-2017M1025392,MYLAN,"KENNY J, DOERHOLT K, GIBB DM, JUDD A. WHO GETS SEVERE GYNECOMASTIA AMONG HIV-INFECTED CHILDREN IN THE UNITED KINGDOM AND IRELAND? PEDIATR-INFECT-DIS-J 2017;36(3):307-310.",,,,,Y,,,20170427,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134923931,OT,,,,,,,,,134923931,1,HIV infection
13495628,134956281,1,I,20131009,20170425,20170428,20170428,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK060424,VIIV,,42,YR,,M,Y,,,20170428,,OT,BR,BR,EFAVIRENZ,Stevens-Johnson syndrome,134956281,LT,,,134956281,1,20131009,,,,134956281,1,HIV infection
13497000,134970001,1,I,,20170421,20170428,20170428,EXP,,US-GILEAD-2017-0269985,GILEAD,,,,,F,Y,,,20170428,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebral toxoplasmosis;Maternal exposure during pregnancy;Oligohydramnios;Premature delivery;Seizure,134970001,OT,,,,,,,,,134970001,1,HIV infection
13497919,134979191,1,I,,20170417,20170428,20170428,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-036581,BRISTOL MYERS SQUIBB,,15,YR,,M,Y,,,20170428,,OT,GB,GB,EFAVIRENZ,Gynaecomastia;Mammoplasty,134979191,OT,,,,,,,,,134979191,1,HIV infection
13497930,134979301,1,I,,20170417,20170428,20170428,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-036579,BRISTOL MYERS SQUIBB,,14,YR,,M,Y,,,20170428,,OT,GB,GB,EFAVIRENZ,Gynaecomastia,134979301,OT,,,,,,,,,134979301,1,HIV infection
13498553,134985531,1,I,2016,20170417,20170501,20170501,EXP,,BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-139256,RANBAXY,,26,YR,,F,Y,,,20170501,,CN,US,BR,Lamivudine/Efavirenz/Tenofovir,Exposure during pregnancy,134985531,OT,,,134985531,3,20161005,20170327,,,134985531,1,Product used for unknown indication
13498554,134985541,1,I,2016,20170417,20170501,20170501,EXP,,BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-139257,RANBAXY,,,,,M,Y,,,20170501,,CN,US,BR,Lamivudine/Efavirenz/Tenofovir,Congenital naevus;Foetal exposure during pregnancy,134985541,OT,,,134985541,1,20161005,20170327,,,134985541,1,Product used for unknown indication
13499846,134998461,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0269949,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134998461,OT,,,,,,,,,134998461,1,Prophylaxis against HIV infection
13499884,134998842,2,F,,20170422,20170501,20170502,EXP,,BW-GILEAD-2017-0270333,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134998842,OT,,,,,,,,,134998842,1,Prophylaxis against HIV infection
13499887,134998871,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270338,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134998871,OT,,,,,,,,,134998871,1,Prophylaxis against HIV infection
13499903,134999032,2,F,,20170422,20170501,20170502,EXP,,BW-GILEAD-2017-0270334,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999032,OT,,,,,,,,,134999032,1,Prophylaxis against HIV infection
13499905,134999052,2,F,,20170422,20170501,20170502,EXP,,BW-GILEAD-2017-0270335,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999052,OT,,,,,,,,,134999052,1,Prophylaxis against HIV infection
13499906,134999061,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270283,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999061,OT,,,,,,,,,134999061,1,Prophylaxis against HIV infection
13499911,134999111,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270336,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999111,OT,,,,,,,,,134999111,1,Prophylaxis against HIV infection
13499918,134999181,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270261,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999181,OT,,,,,,,,,134999181,1,Prophylaxis against HIV infection
13499919,134999191,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270337,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999191,OT,,,,,,,,,134999191,1,Prophylaxis against HIV infection
13499923,134999231,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270260,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999231,OT,,,,,,,,,134999231,1,Prophylaxis against HIV infection
13499932,134999321,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270257,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999321,OT,,,,,,,,,134999321,1,Prophylaxis against HIV infection
13499946,134999461,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270309,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999461,OT,,,,,,,,,134999461,1,Prophylaxis against HIV infection
13499947,134999471,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270259,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999471,OT,,,,,,,,,134999471,1,Prophylaxis against HIV infection
13499948,134999481,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270258,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999481,OT,,,,,,,,,134999481,1,Prophylaxis against HIV infection
13499960,134999601,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270308,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999601,OT,,,,,,,,,134999601,1,Prophylaxis against HIV infection
13499961,134999611,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270329,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999611,OT,,,,,,,,,134999611,1,Prophylaxis against HIV infection
13499967,134999671,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270288,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999671,OT,,,,,,,,,134999671,1,Prophylaxis against HIV infection
13499968,134999681,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270304,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999681,OT,,,,,,,,,134999681,1,Prophylaxis against HIV infection
13499972,134999721,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270331,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999721,OT,,,,,,,,,134999721,1,Prophylaxis against HIV infection
13499975,134999751,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270303,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999751,OT,,,,,,,,,134999751,1,Prophylaxis against HIV infection
13499976,134999761,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270302,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999761,OT,,,,,,,,,134999761,1,Prophylaxis against HIV infection
13499984,134999841,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270300,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999841,OT,,,,,,,,,134999841,1,Prophylaxis against HIV infection
13499989,134999891,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270299,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999891,OT,,,,,,,,,134999891,1,Prophylaxis against HIV infection
13499997,134999971,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270340,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,134999971,OT,,,,,,,,,134999971,1,Prophylaxis against HIV infection
13499999,134999991,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270298,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,134999991,OT,,,,,,,,,134999991,1,Prophylaxis against HIV infection
13500000,135000001,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270347,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000001,OT,,,,,,,,,135000001,1,Prophylaxis against HIV infection
13500003,135000031,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270284,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000031,OT,,,,,,,,,135000031,1,Prophylaxis against HIV infection
13500015,135000151,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270301,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000151,OT,,,,,,,,,135000151,1,Prophylaxis against HIV infection
13500054,135000541,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270262,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000541,OT,,,,,,,,,135000541,1,Prophylaxis against HIV infection
13500089,135000891,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270263,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000891,OT,,,,,,,,,135000891,1,Prophylaxis against HIV infection
13500099,135000991,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270264,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135000991,OT,,,,,,,,,135000991,1,Prophylaxis against HIV infection
13500112,135001121,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270265,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001121,OT,,,,,,,,,135001121,1,Prophylaxis against HIV infection
13500122,135001221,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270297,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001221,OT,,,,,,,,,135001221,1,Prophylaxis against HIV infection
13500125,135001251,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270280,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001251,OT,,,,,,,,,135001251,1,Prophylaxis against HIV infection
13500174,135001741,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270305,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001741,OT,,,,,,,,,135001741,1,Prophylaxis against HIV infection
13500196,135001961,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270310,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135001961,OT,,,,,,,,,135001961,1,Prophylaxis against HIV infection
13500202,135002021,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270281,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002021,OT,,,,,,,,,135002021,1,Prophylaxis against HIV infection
13500216,135002161,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270282,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002161,OT,,,,,,,,,135002161,1,Prophylaxis against HIV infection
13500218,135002181,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270311,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002181,OT,,,,,,,,,135002181,1,Prophylaxis against HIV infection
13500223,135002231,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270312,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002231,OT,,,,,,,,,135002231,1,Prophylaxis against HIV infection
13500224,135002241,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270285,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002241,OT,,,,,,,,,135002241,1,Prophylaxis against HIV infection
13500238,135002381,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270314,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002381,OT,,,,,,,,,135002381,1,Prophylaxis against HIV infection
13500239,135002391,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270286,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002391,OT,,,,,,,,,135002391,1,Prophylaxis against HIV infection
13500241,135002411,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270313,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002411,OT,,,,,,,,,135002411,1,Prophylaxis against HIV infection
13500254,135002541,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270315,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002541,OT,,,,,,,,,135002541,1,Prophylaxis against HIV infection
13500255,135002551,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270287,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002551,OT,,,,,,,,,135002551,1,Prophylaxis against HIV infection
13500276,135002761,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270316,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002761,OT,,,,,,,,,135002761,1,Prophylaxis against HIV infection
13500287,135002871,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270323,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002871,OT,,,,,,,,,135002871,1,Prophylaxis against HIV infection
13500293,135002931,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270324,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135002931,OT,,,,,,,,,135002931,1,Prophylaxis against HIV infection
13500307,135003071,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270325,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135003071,OT,,,,,,,,,135003071,1,Prophylaxis against HIV infection
13500527,135005271,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270326,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005271,OT,,,,,,,,,135005271,1,Prophylaxis against HIV infection
13500536,135005361,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270327,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005361,OT,,,,,,,,,135005361,1,Prophylaxis against HIV infection
13500543,135005431,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270328,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005431,OT,,,,,,,,,135005431,1,Prophylaxis against HIV infection
13500570,135005701,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270330,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,A,F,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,135005701,OT,,,,,,,,,135005701,1,Prophylaxis against HIV infection
13500587,135005871,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270400,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135005871,OT,,,,,,,,,135005871,1,Prophylaxis against HIV infection
13500616,135006161,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270401,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006161,OT,,,,,,,,,135006161,1,Prophylaxis against HIV infection
13500624,135006241,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270402,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006241,OT,,,,,,,,,135006241,1,Prophylaxis against HIV infection
13500645,135006451,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270341,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006451,OT,,,,,,,,,135006451,1,Prophylaxis against HIV infection
13500662,135006621,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270403,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006621,OT,,,,,,,,,135006621,1,Prophylaxis against HIV infection
13500683,135006831,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270411,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006831,OT,,,,,,,,,135006831,1,Prophylaxis against HIV infection
13500694,135006941,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270424,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006941,OT,,,,,,,,,135006941,1,Prophylaxis against HIV infection
13500696,135006961,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270423,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006961,OT,,,,,,,,,135006961,1,Prophylaxis against HIV infection
13500698,135006981,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270385,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135006981,OT,,,,,,,,,135006981,1,Prophylaxis against HIV infection
13500701,135007011,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270418,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007011,OT,,,,,,,,,135007011,1,Prophylaxis against HIV infection
13500702,135007021,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270417,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007021,OT,,,,,,,,,135007021,1,Prophylaxis against HIV infection
13500705,135007051,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270416,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007051,OT,,,,,,,,,135007051,1,Prophylaxis against HIV infection
13500712,135007121,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270407,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007121,OT,,,,,,,,,135007121,1,Prophylaxis against HIV infection
13500714,135007141,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270408,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007141,OT,,,,,,,,,135007141,1,Prophylaxis against HIV infection
13500728,135007281,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270404,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007281,OT,,,,,,,,,135007281,1,Prophylaxis against HIV infection
13500729,135007291,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270412,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007291,OT,,,,,,,,,135007291,1,Prophylaxis against HIV infection
13500744,135007441,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270414,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007441,OT,,,,,,,,,135007441,1,Prophylaxis against HIV infection
13500745,135007451,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270409,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007451,OT,,,,,,,,,135007451,1,Prophylaxis against HIV infection
13500752,135007521,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270386,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007521,OT,,,,,,,,,135007521,1,Prophylaxis against HIV infection
13500759,135007591,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270390,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007591,OT,,,,,,,,,135007591,1,Prophylaxis against HIV infection
13500761,135007611,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270405,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007611,OT,,,,,,,,,135007611,1,Prophylaxis against HIV infection
13500762,135007621,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270410,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007621,OT,,,,,,,,,135007621,1,Prophylaxis against HIV infection
13500763,135007631,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270391,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007631,OT,,,,,,,,,135007631,1,Prophylaxis against HIV infection
13500764,135007641,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270388,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007641,OT,,,,,,,,,135007641,1,Prophylaxis against HIV infection
13500766,135007661,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270394,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007661,OT,,,,,,,,,135007661,1,Prophylaxis against HIV infection
13500791,135007911,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270406,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007911,OT,,,,,,,,,135007911,1,Prophylaxis against HIV infection
13500797,135007971,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270387,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135007971,OT,,,,,,,,,135007971,1,Prophylaxis against HIV infection
13500803,135008031,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270413,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008031,OT,,,,,,,,,135008031,1,Prophylaxis against HIV infection
13500804,135008041,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270415,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008041,OT,,,,,,,,,135008041,1,Prophylaxis against HIV infection
13500834,135008341,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270392,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008341,OT,,,,,,,,,135008341,1,Prophylaxis against HIV infection
13500853,135008531,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270389,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008531,OT,,,,,,,,,135008531,1,Prophylaxis against HIV infection
13500890,135008901,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270393,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135008901,OT,,,,,,,,,135008901,1,Prophylaxis against HIV infection
13501532,135015321,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0269948,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015321,OT,,,,,,,,,135015321,1,Prophylaxis against HIV infection
13501537,135015371,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270436,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015371,OT,,,,,,,,,135015371,1,Prophylaxis against HIV infection
13501539,135015391,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270437,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015391,OT,,,,,,,,,135015391,1,Prophylaxis against HIV infection
13501541,135015411,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270438,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015411,OT,,,,,,,,,135015411,1,Prophylaxis against HIV infection
13501544,135015441,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270439,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015441,OT,,,,,,,,,135015441,1,Prophylaxis against HIV infection
13501545,135015451,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270429,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015451,OT,,,,,,,,,135015451,1,Prophylaxis against HIV infection
13501546,135015461,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270430,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015461,OT,,,,,,,,,135015461,1,Prophylaxis against HIV infection
13501548,135015481,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270431,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015481,OT,,,,,,,,,135015481,1,Prophylaxis against HIV infection
13501552,135015521,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270432,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015521,OT,,,,,,,,,135015521,1,Prophylaxis against HIV infection
13501556,135015561,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270375,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015561,OT,,,,,,,,,135015561,1,Prophylaxis against HIV infection
13501557,135015571,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270370,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015571,OT,,,,,,,,,135015571,1,Prophylaxis against HIV infection
13501558,135015581,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270374,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015581,OT,,,,,,,,,135015581,1,Prophylaxis against HIV infection
13501559,135015591,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270373,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015591,OT,,,,,,,,,135015591,1,Prophylaxis against HIV infection
13501560,135015601,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270376,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015601,OT,,,,,,,,,135015601,1,Prophylaxis against HIV infection
13501561,135015611,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270369,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015611,OT,,,,,,,,,135015611,1,Prophylaxis against HIV infection
13501562,135015621,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270371,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015621,OT,,,,,,,,,135015621,1,Prophylaxis against HIV infection
13501563,135015631,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270372,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015631,OT,,,,,,,,,135015631,1,Prophylaxis against HIV infection
13501564,135015641,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270368,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015641,OT,,,,,,,,,135015641,1,Prophylaxis against HIV infection
13501566,135015661,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270367,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015661,OT,,,,,,,,,135015661,1,Prophylaxis against HIV infection
13501587,135015871,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270342,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015871,OT,,,,,,,,,135015871,1,Prophylaxis against HIV infection
13501588,135015881,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270425,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015881,OT,,,,,,,,,135015881,1,Prophylaxis against HIV infection
13501589,135015891,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270426,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015891,OT,,,,,,,,,135015891,1,Prophylaxis against HIV infection
13501590,135015901,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270427,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015901,OT,,,,,,,,,135015901,1,Prophylaxis against HIV infection
13501594,135015941,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270428,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015941,OT,,,,,,,,,135015941,1,Prophylaxis against HIV infection
13501595,135015951,1,I,,20170422,20170501,20170501,EXP,,BW-GILEAD-2017-0270339,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170501,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135015951,OT,,,,,,,,,135015951,1,Prophylaxis against HIV infection
13504041,135040411,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270441,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040411,OT,,,,,,,,,135040411,1,Prophylaxis against HIV infection
13504044,135040441,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270443,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040441,OT,,,,,,,,,135040441,1,Prophylaxis against HIV infection
13504046,135040461,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270445,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040461,OT,,,,,,,,,135040461,1,Prophylaxis against HIV infection
13504065,135040651,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270452,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040651,OT,,,,,,,,,135040651,1,Prophylaxis against HIV infection
13504066,135040661,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270454,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040661,OT,,,,,,,,,135040661,1,Prophylaxis against HIV infection
13504067,135040671,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270450,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040671,OT,,,,,,,,,135040671,1,Prophylaxis against HIV infection
13504083,135040831,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270457,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040831,OT,,,,,,,,,135040831,1,Prophylaxis against HIV infection
13504092,135040921,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270462,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040921,OT,,,,,,,,,135040921,1,Prophylaxis against HIV infection
13504097,135040971,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270465,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135040971,OT,,,,,,,,,135040971,1,Prophylaxis against HIV infection
13504107,135041071,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270468,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041071,OT,,,,,,,,,135041071,1,Prophylaxis against HIV infection
13504109,135041091,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270470,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041091,OT,,,,,,,,,135041091,1,Prophylaxis against HIV infection
13504134,135041341,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270477,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041341,OT,,,,,,,,,135041341,1,Prophylaxis against HIV infection
13504165,135041651,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270478,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041651,OT,,,,,,,,,135041651,1,Prophylaxis against HIV infection
13504167,135041671,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270512,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041671,OT,,,,,,,,,135041671,1,Prophylaxis against HIV infection
13504174,135041741,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270514,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041741,OT,,,,,,,,,135041741,1,Prophylaxis against HIV infection
13504188,135041881,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270518,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135041881,OT,,,,,,,,,135041881,1,Prophylaxis against HIV infection
13504210,135042101,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270519,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042101,OT,,,,,,,,,135042101,1,Prophylaxis against HIV infection
13504225,135042251,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270515,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042251,OT,,,,,,,,,135042251,1,Prophylaxis against HIV infection
13504226,135042261,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270524,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042261,OT,,,,,,,,,135042261,1,Prophylaxis against HIV infection
13504232,135042321,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270526,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042321,OT,,,,,,,,,135042321,1,Prophylaxis against HIV infection
13504240,135042401,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270528,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042401,OT,,,,,,,,,135042401,1,Prophylaxis against HIV infection
13504273,135042731,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270442,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042731,OT,,,,,,,,,135042731,1,Prophylaxis against HIV infection
13504274,135042741,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270684,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042741,OT,,,,,,,,,135042741,1,Prophylaxis against HIV infection
13504275,135042751,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270529,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042751,OT,,,,,,,,,135042751,1,Prophylaxis against HIV infection
13504277,135042771,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270531,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042771,OT,,,,,,,,,135042771,1,Prophylaxis against HIV infection
13504278,135042781,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270682,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042781,OT,,,,,,,,,135042781,1,Prophylaxis against HIV infection
13504288,135042881,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270537,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042881,OT,,,,,,,,,135042881,1,Prophylaxis against HIV infection
13504289,135042891,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270671,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042891,OT,,,,,,,,,135042891,1,Prophylaxis against HIV infection
13504292,135042921,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270440,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042921,OT,,,,,,,,,135042921,1,Prophylaxis against HIV infection
13504294,135042941,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270670,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135042941,OT,,,,,,,,,135042941,1,Prophylaxis against HIV infection
13504302,135043021,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270444,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043021,OT,,,,,,,,,135043021,1,Prophylaxis against HIV infection
13504312,135043121,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270669,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043121,OT,,,,,,,,,135043121,1,Prophylaxis against HIV infection
13504313,135043131,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270449,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043131,OT,,,,,,,,,135043131,1,Prophylaxis against HIV infection
13504314,135043141,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270672,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043141,OT,,,,,,,,,135043141,1,Prophylaxis against HIV infection
13504326,135043261,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270539,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043261,OT,,,,,,,,,135043261,1,Prophylaxis against HIV infection
13504334,135043341,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270665,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043341,OT,,,,,,,,,135043341,1,Prophylaxis against HIV infection
13504345,135043451,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270451,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043451,OT,,,,,,,,,135043451,1,Prophylaxis against HIV infection
13504346,135043461,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270668,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043461,OT,,,,,,,,,135043461,1,Prophylaxis against HIV infection
13504347,135043471,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270674,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043471,OT,,,,,,,,,135043471,1,Prophylaxis against HIV infection
13504349,135043491,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270667,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043491,OT,,,,,,,,,135043491,1,Prophylaxis against HIV infection
13504353,135043531,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270666,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043531,OT,,,,,,,,,135043531,1,Prophylaxis against HIV infection
13504354,135043541,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270678,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043541,OT,,,,,,,,,135043541,1,Prophylaxis against HIV infection
13504357,135043571,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270540,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043571,OT,,,,,,,,,135043571,1,Prophylaxis against HIV infection
13504358,135043581,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270676,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043581,OT,,,,,,,,,135043581,1,Prophylaxis against HIV infection
13504359,135043591,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270453,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043591,OT,,,,,,,,,135043591,1,Prophylaxis against HIV infection
13504360,135043601,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270661,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043601,OT,,,,,,,,,135043601,1,Prophylaxis against HIV infection
13504361,135043611,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270662,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043611,OT,,,,,,,,,135043611,1,Prophylaxis against HIV infection
13504362,135043621,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270648,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043621,OT,,,,,,,,,135043621,1,Prophylaxis against HIV infection
13504364,135043641,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270680,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043641,OT,,,,,,,,,135043641,1,Prophylaxis against HIV infection
13504365,135043651,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270663,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043651,OT,,,,,,,,,135043651,1,Prophylaxis against HIV infection
13504366,135043661,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270664,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043661,OT,,,,,,,,,135043661,1,Prophylaxis against HIV infection
13504368,135043681,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270543,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043681,OT,,,,,,,,,135043681,1,Prophylaxis against HIV infection
13504376,135043761,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270455,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043761,OT,,,,,,,,,135043761,1,Prophylaxis against HIV infection
13504377,135043771,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270660,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043771,OT,,,,,,,,,135043771,1,Prophylaxis against HIV infection
13504378,135043781,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270546,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043781,OT,,,,,,,,,135043781,1,Prophylaxis against HIV infection
13504387,135043871,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270549,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135043871,OT,,,,,,,,,135043871,1,Prophylaxis against HIV infection
13504411,135044111,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270552,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044111,OT,,,,,,,,,135044111,1,Prophylaxis against HIV infection
13504413,135044131,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270456,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044131,OT,,,,,,,,,135044131,1,Prophylaxis against HIV infection
13504419,135044191,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270556,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044191,OT,,,,,,,,,135044191,1,Prophylaxis against HIV infection
13504431,135044311,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270559,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044311,OT,,,,,,,,,135044311,1,Prophylaxis against HIV infection
13504432,135044321,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270658,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044321,OT,,,,,,,,,135044321,1,Prophylaxis against HIV infection
13504433,135044331,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270659,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044331,OT,,,,,,,,,135044331,1,Prophylaxis against HIV infection
13504446,135044461,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270563,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044461,OT,,,,,,,,,135044461,1,Prophylaxis against HIV infection
13504447,135044471,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270656,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044471,OT,,,,,,,,,135044471,1,Prophylaxis against HIV infection
13504449,135044491,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270657,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044491,OT,,,,,,,,,135044491,1,Prophylaxis against HIV infection
13504456,135044561,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270655,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135044561,OT,,,,,,,,,135044561,1,Prophylaxis against HIV infection
13504518,135045181,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270654,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135045181,OT,,,,,,,,,135045181,1,Prophylaxis against HIV infection
13504624,135046241,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270653,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135046241,OT,,,,,,,,,135046241,1,Prophylaxis against HIV infection
13504708,135047081,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270651,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047081,OT,,,,,,,,,135047081,1,Prophylaxis against HIV infection
13504709,135047091,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270650,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047091,OT,,,,,,,,,135047091,1,Prophylaxis against HIV infection
13504721,135047211,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270625,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047211,OT,,,,,,,,,135047211,1,Prophylaxis against HIV infection
13504725,135047251,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270649,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047251,OT,,,,,,,,,135047251,1,Prophylaxis against HIV infection
13504761,135047611,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270523,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047611,OT,,,,,,,,,135047611,1,Prophylaxis against HIV infection
13504762,135047621,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270475,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047621,OT,,,,,,,,,135047621,1,Prophylaxis against HIV infection
13504790,135047901,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270646,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047901,OT,,,,,,,,,135047901,1,Prophylaxis against HIV infection
13504791,135047911,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270647,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047911,OT,,,,,,,,,135047911,1,Prophylaxis against HIV infection
13504792,135047921,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270463,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135047921,OT,,,,,,,,,135047921,1,Prophylaxis against HIV infection
13504835,135048351,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270525,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048351,OT,,,,,,,,,135048351,1,Prophylaxis against HIV infection
13504847,135048471,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270527,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048471,OT,,,,,,,,,135048471,1,Prophylaxis against HIV infection
13504849,135048491,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270561,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048491,OT,,,,,,,,,135048491,1,Prophylaxis against HIV infection
13504850,135048501,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270565,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048501,OT,,,,,,,,,135048501,1,Prophylaxis against HIV infection
13504851,135048511,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270553,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048511,OT,,,,,,,,,135048511,1,Prophylaxis against HIV infection
13504852,135048521,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270530,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048521,OT,,,,,,,,,135048521,1,Prophylaxis against HIV infection
13504853,135048531,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270516,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048531,OT,,,,,,,,,135048531,1,Prophylaxis against HIV infection
13504864,135048641,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270538,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048641,OT,,,,,,,,,135048641,1,Prophylaxis against HIV infection
13504865,135048651,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270517,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048651,OT,,,,,,,,,135048651,1,Prophylaxis against HIV infection
13504866,135048661,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270532,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048661,OT,,,,,,,,,135048661,1,Prophylaxis against HIV infection
13504874,135048741,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270464,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048741,OT,,,,,,,,,135048741,1,Prophylaxis against HIV infection
13504877,135048771,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270541,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048771,OT,,,,,,,,,135048771,1,Prophylaxis against HIV infection
13504878,135048781,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270564,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048781,OT,,,,,,,,,135048781,1,Prophylaxis against HIV infection
13504890,135048901,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270544,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048901,OT,,,,,,,,,135048901,1,Prophylaxis against HIV infection
13504891,135048911,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270557,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135048911,OT,,,,,,,,,135048911,1,Prophylaxis against HIV infection
13504924,135049241,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270554,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049241,OT,,,,,,,,,135049241,1,Prophylaxis against HIV infection
13504925,135049251,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270458,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049251,OT,,,,,,,,,135049251,1,Prophylaxis against HIV infection
13504926,135049261,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270466,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049261,OT,,,,,,,,,135049261,1,Prophylaxis against HIV infection
13504929,135049291,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270548,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049291,OT,,,,,,,,,135049291,1,Prophylaxis against HIV infection
13504939,135049391,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270555,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049391,OT,,,,,,,,,135049391,1,Prophylaxis against HIV infection
13504945,135049451,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270467,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049451,OT,,,,,,,,,135049451,1,Prophylaxis against HIV infection
13504951,135049511,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270469,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049511,OT,,,,,,,,,135049511,1,Prophylaxis against HIV infection
13504952,135049521,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270679,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049521,OT,,,,,,,,,135049521,1,Prophylaxis against HIV infection
13504955,135049551,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270551,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049551,OT,,,,,,,,,135049551,1,Prophylaxis against HIV infection
13504956,135049561,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270566,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049561,OT,,,,,,,,,135049561,1,Prophylaxis against HIV infection
13504957,135049571,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270677,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049571,OT,,,,,,,,,135049571,1,Prophylaxis against HIV infection
13504958,135049581,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270675,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049581,OT,,,,,,,,,135049581,1,Prophylaxis against HIV infection
13504959,135049591,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270547,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049591,OT,,,,,,,,,135049591,1,Prophylaxis against HIV infection
13504960,135049601,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270550,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049601,OT,,,,,,,,,135049601,1,Prophylaxis against HIV infection
13504965,135049651,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270562,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049651,OT,,,,,,,,,135049651,1,Prophylaxis against HIV infection
13504969,135049691,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270471,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049691,OT,,,,,,,,,135049691,1,Prophylaxis against HIV infection
13504975,135049751,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270683,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049751,OT,,,,,,,,,135049751,1,Prophylaxis against HIV infection
13504995,135049951,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270476,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049951,OT,,,,,,,,,135049951,1,Prophylaxis against HIV infection
13504999,135049991,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270479,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135049991,OT,,,,,,,,,135049991,1,Prophylaxis against HIV infection
13505014,135050141,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270542,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050141,OT,,,,,,,,,135050141,1,Prophylaxis against HIV infection
13505015,135050151,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270510,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050151,OT,,,,,,,,,135050151,1,Prophylaxis against HIV infection
13505020,135050201,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270482,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050201,OT,,,,,,,,,135050201,1,Prophylaxis against HIV infection
13505037,135050371,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270513,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135050371,OT,,,,,,,,,135050371,1,Prophylaxis against HIV infection
13505171,135051711,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270681,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135051711,OT,,,,,,,,,135051711,1,Prophylaxis against HIV infection
13505172,135051721,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270545,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135051721,OT,,,,,,,,,135051721,1,Prophylaxis against HIV infection
13505173,135051731,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270560,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135051731,OT,,,,,,,,,135051731,1,Prophylaxis against HIV infection
13505268,135052681,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270558,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135052681,OT,,,,,,,,,135052681,1,Prophylaxis against HIV infection
13505305,135053051,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270652,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135053051,OT,,,,,,,,,135053051,1,Prophylaxis against HIV infection
13505430,135054301,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270619,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135054301,OT,,,,,,,,,135054301,1,Prophylaxis against HIV infection
13505488,135054881,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270620,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135054881,OT,,,,,,,,,135054881,1,Prophylaxis against HIV infection
13505489,135054891,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270624,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135054891,OT,,,,,,,,,135054891,1,Prophylaxis against HIV infection
13505598,135055981,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270626,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135055981,OT,,,,,,,,,135055981,1,Prophylaxis against HIV infection
13505607,135056071,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270627,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056071,OT,,,,,,,,,135056071,1,Prophylaxis against HIV infection
13505611,135056111,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270628,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056111,OT,,,,,,,,,135056111,1,Prophylaxis against HIV infection
13505617,135056171,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270645,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056171,OT,,,,,,,,,135056171,1,Prophylaxis against HIV infection
13505625,135056251,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270621,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135056251,OT,,,,,,,,,135056251,1,Prophylaxis against HIV infection
13505738,135057381,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270623,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135057381,OT,,,,,,,,,135057381,1,Prophylaxis against HIV infection
13506246,135062461,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270480,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135062461,OT,,,,,,,,,135062461,1,Prophylaxis against HIV infection
13506247,135062471,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270481,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135062471,OT,,,,,,,,,135062471,1,Prophylaxis against HIV infection
13506464,135064641,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270483,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135064641,OT,,,,,,,,,135064641,1,Prophylaxis against HIV infection
13506498,135064981,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270484,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135064981,OT,,,,,,,,,135064981,1,Prophylaxis against HIV infection
13506594,135065941,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270511,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135065941,OT,,,,,,,,,135065941,1,Prophylaxis against HIV infection
13506753,135067531,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270622,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135067531,OT,,,,,,,,,135067531,1,Prophylaxis against HIV infection
13506754,135067541,1,I,,20170422,20170502,20170502,EXP,,BW-GILEAD-2017-0270673,GILEAD,"ZASH R, SOUDA S, CHEN J, BINDA K, DRYDEN-PETERSON S, LOCKMAN S, MMALANE M, MAKHEMA J, ESSEX M, SHAPIRO R. REASSURING BIRTH OUTCOMES WITH TENOFOVIR/EMTRICITABINE/EFAVIRENZ USED FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV IN BOTSWANA.. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;71(4):428-436",,,I,,Y,,,20170502,,MD,BW,BW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Small for dates baby,135067541,OT,,,,,,,,,135067541,1,Prophylaxis against HIV infection
13510629,135106291,1,I,,20170420,20170503,20170503,EXP,,US-MYLANLABS-2017M1026353,MYLAN,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT. OPEN-FORUM-INFECT-DIS 2017;4(1):1-4.",,,,,Y,,,20170503,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis,135106291,OT,,,,,,,,,135106291,1,HIV infection
13510925,135109251,1,I,,20170420,20170503,20170503,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038065,BRISTOL MYERS SQUIBB,,24,YR,,M,Y,,,20170503,,OT,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis coronary artery,135109251,OT,,,,,,,,,135109251,1,HIV infection
13513827,135138271,1,I,,20170424,20170504,20170504,EXP,,US-MYLANLABS-2017M1026998,MYLAN,"KIA L, BEATTIE A, GREEN RM. AUTOIMMUNE HEPATITIS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): CASE REPORTS OF A RARE, BUT IMPORTANT DIAGNOSIS WITH THERAPEUTIC IMPLICATIONS. MEDICINE 2017;96(7):E6011.",,,,,Y,,,20170504,,MD,US,US,EFAVIRENZ,Acute hepatic failure;Autoimmune hepatitis;Sepsis;Toxicity to various agents,135138271,HO,,,,,,,,,135138271,1,HIV infection
13514585,135145851,1,I,,20170314,20170504,20170504,PER,,US-STRIDES ARCOLAB LIMITED-2017SP004844,STRIDES,"WALENSKY RP, GOLDBERG JH, DAILY JP. ANAPHYLAXIS AFTER RECHALLENGE WITH ABACAVIR. AIDS. 1999;13(8):999-1000",,,,,Y,,,20170504,,OT,US,US,EFAVIRENZ,Anaphylactic reaction;Chest discomfort;Chills;Dermatitis exfoliative;Diarrhoea;Dyspnoea;Hypotension;Ischaemia;Pyrexia;Rash erythematous;Rash macular;Stomatitis,135145851,HO,,,,,,,,,135145851,1,Acquired immunodeficiency syndrome
13514904,135149041,1,I,,20170424,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038108,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170504,,OT,US,US,EFAVIRENZ,Acute hepatic failure;Autoimmune hepatitis;Liver transplant;Toxicity to various agents,135149041,OT,,,,,,,,,135149041,1,HIV test
13515106,135151061,1,I,201112,20120724,20170504,20170504,EXP,,BR-GLAXOSMITHKLINE-B0818935A,GLAXOSMITHKLINE,DE ALMEIDA S.M AND ROZA T.H. HIV IMMUNE RECOVERY INFLAMMATORY SYNDROME AND CENTRAL NERVOUS SYSTEM PARACOCCIDIOIDOMYCOSIS. MYCOPATHOLOGIA. 2017;182:3-4:393-396,35,YR,,M,Y,,,20170504,,OT,BR,BR,Efavirenz,Aggression;Agitation;Brain oedema;Central nervous system lesion;Confusional state;Coordination abnormal;Dizziness;Dysarthria;Encephalitis;Hyperreflexia;Immune reconstitution inflammatory syndrome;Irritability;Paracoccidioides infection;Phonophobia;Psychomotor hyperactivity;Speech disorder;Syncope,135151061,HO,,,,,,,,,135151061,1,Product used for unknown indication
13515130,135151301,1,I,,20170426,20170504,20170504,EXP,,US-GILEAD-2017-0270355,GILEAD,,48,YR,A,F,Y,,,20170504,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus,135151301,OT,,,135151301,1,2009,,,,135151301,1,HIV infection
13515208,135152081,1,I,,20170428,20170504,20170504,EXP,,CA-GILEAD-2017-0270615,GILEAD,,52,YR,A,M,Y,,,20170504,,OT,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135152081,OT,,,,,,,,,135152081,1,HIV infection
13515529,135155291,1,I,,20170424,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038930,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170504,,OT,US,US,EFAVIRENZ,Autoimmune hepatitis;Toxicity to various agents,135155291,OT,,,,,,,,,135155291,1,HIV test
13515530,135155301,1,I,,20170424,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038931,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170504,,OT,US,US,EFAVIRENZ,Autoimmune hepatitis;Toxicity to various agents,135155301,OT,,,,,,,,,135155301,1,HIV test
13515535,135155351,1,I,,20170424,20170504,20170504,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038932,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170504,,OT,US,US,EFAVIRENZ,Autoimmune hepatitis;Toxicity to various agents,135155351,OT,,,,,,,,,135155351,1,HIV test
13515593,135155931,1,I,,20170421,20170504,20170504,EXP,,CA-GILEAD-2017-0269568,GILEAD,,35,YR,A,M,Y,,,20170504,,OT,CA,CA,EFAVIRENZ,HIV viraemia;Nephropathy toxic;Therapeutic response decreased,135155931,OT,,,,,,,,,135155931,1,HIV infection
13517606,135176061,1,I,20160715,,20170505,20170505,DIR,FDA-CDER-CTU-2017-27058,,FDA-CTU,,44,YR,,M,N,79.4,KG,20161222,N,PH,US,US,SUSTIVA,Haemorrhage;Headache;Hypoglycaemia,135176061,HO,135176061,HP,,,,,,,135176061,1,Diabetes mellitus
13517731,135177311,1,I,201112,20120724,20170505,20170505,EXP,,BR-VIIV HEALTHCARE LIMITED-B0818935A,VIIV,DE ALMEIDA S.M AND ROZA T.H. HIV IMMUNE RECOVERY INFLAMMATORY SYNDROME AND CENTRAL NERVOUS SYSTEM PARACOCCIDIOIDOMYCOSIS. MYCOPATHOLOGIA. 2017;182:3-4:393-396,35,YR,,M,Y,,,20170505,,OT,BR,BR,Efavirenz,Aggression;Agitation;Brain oedema;Central nervous system lesion;Confusional state;Coordination abnormal;Dizziness;Dysarthria;Encephalitis;Hyperreflexia;Immune reconstitution inflammatory syndrome;Irritability;Paracoccidioides infection;Phonophobia;Psychomotor hyperactivity;Speech disorder;Syncope,135177311,HO,,,,,,,,,135177311,1,Product used for unknown indication
13518041,135180411,1,I,,20170427,20170505,20170505,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-037419,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20170505,,CN,US,US,SUSTIVA,Dialysis;Visual impairment,135180411,OT,,,,,,,,,135180411,1,HIV infection
13520796,135207961,1,I,,20170426,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07939,CIPLA,,,,,,Y,,,20170508,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135207961,OT,,,,,,,,,135207961,1,HIV infection
13520802,135208021,1,I,,20170426,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07936,CIPLA,,,,,,Y,,,20170508,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135208021,OT,,,,,,,,,135208021,1,HIV infection
13520804,135208041,1,I,,20170426,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07938,CIPLA,,,,,,Y,,,20170508,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135208041,OT,,,,,,,,,135208041,1,HIV infection
13520813,135208131,1,I,,20170426,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07935,CIPLA,,,,,,Y,,,20170508,,OT,FR,BF,Efavirenz,Virologic failure,135208131,OT,,,,,,,,,135208131,1,HIV infection
13520815,135208151,1,I,,20170426,20170508,20170508,EXP,,BF-CIPLA LTD.-2017BF07937,CIPLA,,,,,,Y,,,20170508,,OT,FR,BF,Efavirenz,Drug resistance;Virologic failure,135208151,OT,,,,,,,,,135208151,1,HIV infection
13521928,135219281,1,I,,20170428,20170508,20170508,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2017065893,VIIV,UNK. UNK. UNK. UNK;UNK:UNK,52,YR,,M,Y,,,20170508,,OT,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135219281,OT,,,,,,,,,135219281,1,HIV infection
13522021,135220211,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027030,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220211,OT,,,,,,,,,135220211,1,HIV infection
13522023,135220231,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027029,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220231,OT,,,,,,,,,135220231,1,HIV infection
13522025,135220251,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027031,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220251,OT,,,,,,,,,135220251,1,HIV infection
13522026,135220261,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027032,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220261,OT,,,,,,,,,135220261,1,HIV infection
13522034,135220341,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027033,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135220341,OT,,,,,,,,,135220341,1,HIV infection
13522216,135222161,1,I,,20170428,20170508,20170508,EXP,,CA-GLAXOSMITHKLINE-CA2017065893,GLAXOSMITHKLINE,UNK. UNK. UNK. UNK;UNK:UNK,52,YR,,M,Y,,,20170508,,OT,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,135222161,OT,,,,,,,,,135222161,1,HIV infection
13522269,135222691,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027049,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222691,OT,,,,,,,,,135222691,1,HIV infection
13522270,135222701,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027047,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222701,OT,,,,,,,,,135222701,1,HIV infection
13522271,135222711,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027050,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222711,OT,,,,,,,,,135222711,1,HIV infection
13522272,135222721,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027054,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222721,OT,,,,,,,,,135222721,1,HIV infection
13522274,135222741,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027053,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222741,OT,,,,,,,,,135222741,1,HIV infection
13522276,135222761,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027051,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222761,OT,,,,,,,,,135222761,1,HIV infection
13522277,135222771,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027055,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135222771,OT,,,,,,,,,135222771,1,HIV infection
13522365,135223651,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027061,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223651,OT,,,,,,,,,135223651,1,HIV infection
13522366,135223661,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027060,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223661,OT,,,,,,,,,135223661,1,HIV infection
13522368,135223681,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027057,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223681,OT,,,,,,,,,135223681,1,HIV infection
13522369,135223691,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027056,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223691,OT,,,,,,,,,135223691,1,HIV infection
13522371,135223711,1,I,,20170425,20170508,20170508,EXP,,ET-MYLANLABS-2017M1027065,MYLAN,"PETROS Z, KISHIKAWA J, MAKONNEN E, YIMER G, HABTEWOLD A, AKLILLU E. HLA-B*57 ALLELE IS ASSOCIATED WITH CONCOMITANT ANTI-TUBERCULOSIS AND ANTIRETROVIRAL DRUGS INDUCED LIVER TOXICITY IN ETHIOPIANS. FRONT-PHARMACOL 2017;8:90.",,,,,Y,,,20170508,,OT,ET,ET,EFAVIRENZ,Drug-induced liver injury,135223711,OT,,,,,,,,,135223711,1,HIV infection
13523657,135236571,1,I,201701,20170125,20170508,20170508,PER,,US-VIFOR (INTERNATIONAL) INC.-VIT-2017-00865,VIFOR,,67,YR,,F,Y,,,20170508,,OT,US,US,SUSTIVA,No adverse event;Off label use,,,,,135236571,1,201701,,,,135236571,1,Hyperkalaemia
13523816,135238161,1,I,20170408,20170428,20170508,20170508,EXP,,ZA-GILEAD-2017-0270985,GILEAD,,43,YR,A,M,Y,60.6,KG,20170508,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Thermal burn,135238161,HO,,,135238161,1,20150817,,,,135238161,1,HIV infection
13526370,135263701,1,I,,20170501,20170509,20170509,EXP,,US-HETERO LABS LTD-2020436,HETERO,,24,YR,,M,Y,,,20170509,,OT,US,US,Efavirenz,Acute myocardial infarction;Arteriosclerosis,135263701,OT,,,,,,,,,135263701,1,HIV infection
13526383,135263831,1,I,,20170501,20170509,20170509,EXP,,IN-HETERO LABS LTD-2020438,HETERO,,,,,,Y,,,20170509,,OT,IN,IN,Efavirenz,Stevens-Johnson syndrome,135263831,OT,,,,,,,,,135263831,1,HIV infection
13528637,135286371,1,I,,20170501,20170509,20170509,EXP,,US-TEVA-766033USA,TEVA,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT. OPEN-FORUM-INFECT-DIS 2017;4(1):1-4.",24,YR,,M,Y,,,20170509,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis,135286371,HO,,,,,,,,,135286371,1,HIV infection
13531770,135317701,1,I,20170411,20170503,20170510,20170510,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2017GSK067339,VIIV,,19,YR,,F,Y,47.2,KG,20170510,,MD,BR,BR,Efavirenz,Overdose,135317701,OT,,,135317701,1,20170309,20170417,,,135317701,1,HIV infection
13533460,135334603,3,F,20170206,20170602,20170510,20170609,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-029622,BRISTOL MYERS SQUIBB,,,,,M,Y,2.8,KG,20170609,,OT,BR,BR,EFAVIRENZ,Ankyloglossia congenital;Foetal distress syndrome;Foetal exposure during pregnancy;Strabismus congenital,135334603,CA,,,135334603,1,20161021,20170205,,,135334603,1,Product used for unknown indication
13536066,135360662,2,F,,20170605,20170511,20170615,EXP,,DE-GILEAD-2017-0272168,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",62,YR,A,M,Y,,,20170615,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema;Stress fracture,135360662,OT,,,,,,,,,135360662,1,HIV infection
13536662,135366621,1,I,,20170510,20170511,20170511,PER,,US-BAYER-2017-089183,BAYER,,65,YR,E,M,Y,82,KG,20170511,,CN,US,US,EFAVIRENZ;SUSTIVA,Off label use;Product use in unapproved indication;Product use issue,,,,,135366621,1,,20170510,,,135366621,1,Constipation
13537406,135374063,3,F,20170411,20170516,20170511,20170522,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-040783,BRISTOL MYERS SQUIBB,,19,YR,,F,Y,50,KG,20170522,,OT,BR,BR,EFAVIRENZ,Drug dose omission;Insomnia;Maternal exposure during pregnancy;Overdose,135374063,OT,,,135374063,1,20170309,20170417,,,135374063,1,HIV infection
13539634,135396341,1,I,,20170428,20170512,20170512,EXP,,US-MYLANLABS-2017M1028036,MYLAN,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",,,,,Y,,,20170512,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Herpes zoster;Neutropenia,135396341,OT,,,,,,,,,135396341,1,Lymphoma AIDS related
13540226,135402261,1,I,,20170428,20170512,20170512,EXP,,US-MYLANLABS-2017M1028180,MYLAN,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",,,,,Y,,,20170512,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased;Aspartate aminotransferase increased;Neutropenia;Renal failure,135402261,OT,,,,,,,,,135402261,1,Lymphoma AIDS related
13540227,135402271,1,I,,20170428,20170512,20170512,EXP,,US-MYLANLABS-2017M1028177,MYLAN,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",,,,,Y,,,20170512,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased,135402271,OT,,,,,,,,,135402271,1,Lymphoma AIDS related
13540243,135402431,1,I,,20170428,20170512,20170512,EXP,,US-MYLANLABS-2017M1028043,MYLAN,"AZAR MM, MALINIS MF, MOSS J, FORMICA RN, VILLANUEVA MS. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT-J-STD-AIDS 2017;28(5):447-458.",,,,,Y,,,20170512,,OT,US,US,EFAVIRENZ,Chronic allograft nephropathy;Drug interaction;Transplant failure,135402431,OT,,,,,,,,,135402431,1,HIV infection
13540293,135402931,1,I,,20170428,20170512,20170512,EXP,,US-MYLANLABS-2017M1028103,MYLAN,"AZAR MM, MALINIS MF, MOSS J, FORMICA RN, VILLANUEVA MS. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT-J-STD-AIDS 2017;28(5):447-458.",,,,,Y,,,20170512,,OT,US,US,EFAVIRENZ,Chronic allograft nephropathy;Drug interaction;Toxicity to various agents;Transplant failure;Transplant rejection,135402931,OT,,,,,,,,,135402931,1,HIV infection
13541292,135412921,1,I,,20170504,20170512,20170512,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-039217,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20170512,,MD,US,US,EFAVIRENZ,Lip and/or oral cavity cancer,135412921,OT,,,,,,,,,135412921,1,HIV infection
13543072,135430721,1,I,20170510,,20170512,20170512,DIR,FDA-CDER-CTU-2017-28704,,FDA-CTU,,63,YR,,F,N,,,20170512,N,PH,US,US,SUSTIVA,Hiatus hernia,,,135430721,HP,,,,,,,,,
13549436,135494361,1,I,,20170508,20170516,20170516,EXP,,US-TEVA-768207USA,TEVA,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",51,YR,,M,Y,,,20170516,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE",Alanine aminotransferase increased;Aspartate aminotransferase increased;Neutropenia;Renal failure,135494361,OT,,,,,,,,,135494361,1,Lymphoma AIDS related
13549468,135494681,1,I,,20170508,20170516,20170516,EXP,,US-TEVA-768216USA,TEVA,"GUPTA NK, NOLAN A, OMURO A, REID EG, WANG C-C, MANNIS G, ET AL. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO-ONCOL 2017;19(1):99-108.",65,YR,,M,Y,,,20170516,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE",Herpes zoster;Neutropenia,135494681,OT,,,,,,,,,135494681,1,Lymphoma AIDS related
13549472,135494722,2,F,,20170511,20170516,20170525,EXP,,US-AUROBINDO-AUR-APL-2017-33903,AUROBINDO,,44,YR,,M,Y,,,20170525,,OT,US,US,EFAVIRENZ,Blood triglycerides increased;Diabetes mellitus;Fatigue;Insomnia;Polydipsia;Polyuria;Vision blurred;Weight decreased,135494722,OT,,,,,,,,,135494722,1,Product used for unknown indication
13549769,135497691,1,I,,20170505,20170516,20170516,EXP,,US-STRIDES ARCOLAB LIMITED-2017SP007467,STRIDES,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL.. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT.. OPEN-FORUM-INFECT-DIS. 2017;4(1):1-4",,,,,Y,,,20170516,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis;Chest pain;Discomfort;Hyperhidrosis,135497691,HO,,,,,,,,,135497691,1,Perinatal HIV infection
13549770,135497701,1,I,,20170511,20170516,20170516,EXP,,US-STRIDES ARCOLAB LIMITED-2017SP007820,STRIDES,"AZAR MM, MALINIS MF, MOSS J, FORMICA RN, VILLANUEVA MS. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT J STD AIDS. 2017;28(5):447-458",,,,,Y,,,20170516,,OT,US,US,EFAVIRENZ,Chronic allograft nephropathy;Drug interaction;Drug level below therapeutic;Transplant failure;Transplant rejection,135497701,OT,,,,,,,,,135497701,1,Renal transplant
13549791,135497911,1,I,,20170511,20170516,20170516,EXP,,US-STRIDES ARCOLAB LIMITED-2017SP007741,STRIDES,"AZAR MM, MALINIS MF, MOSS J, FORMICA RN, VILLANUEVA MS. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT J STD AIDS. 2017;28(5):447-458",,,,,Y,,,20170516,,OT,US,US,EFAVIRENZ,Chronic allograft nephropathy;Drug interaction;Drug level below therapeutic;Transplant failure;Transplant rejection,135497911,OT,,,,,,,,,135497911,1,Renal transplant
13550865,135508651,1,I,20160623,20160830,20170516,20170516,EXP,,"US-THERATECHNOLOGIES, INC.-TH-2016-00112",THERATECHNOLOGIES,,53,YR,,M,Y,126,KG,20170516,,MD,US,US,SUSTIVA,Affective disorder,135508651,HO,,,135508651,1,20150317,20160128,,,135508651,1,Lipodystrophy acquired
13551832,135518321,1,I,,20170501,20170516,20170516,EXP,,US-GLAXOSMITHKLINE-US2017GSK072067,GLAXOSMITHKLINE,"SCOTT GB, BROGLY SB, MUENZ D, STEK AM, READ JS.. MISSED OPPORTUNITIES FOR PREVENTION OF MOTHER -TO-CHILD TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS. OBSTETRICS + GYNECOLOGY. 2017;129 (4):621-628",,,,M,Y,,,20170516,,MD,US,US,EFAVIRENZ,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,135518321,OT,,,,,,,,,135518321,1,HIV infection
13551837,135518371,1,I,,20170501,20170516,20170516,EXP,,US-VIIV HEALTHCARE LIMITED-US2017GSK072067,VIIV,"SCOTT GB, BROGLY SB, MUENZ D, STEK AM, READ JS.. MISSED OPPORTUNITIES FOR PREVENTION OF MOTHER -TO-CHILD TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS. OBSTETRICS + GYNECOLOGY. 2017;129 (4):621-628",,,,M,Y,,,20170516,,MD,US,US,EFAVIRENZ,Foetal exposure during pregnancy;HIV infection;Human immunodeficiency virus transmission,135518371,OT,,,,,,,,,135518371,1,HIV infection
13560599,135605991,1,I,,20170508,20170518,20170518,EXP,,US-FRESENIUS KABI-FK201704161,FRESENIUS KABI,"GUPTA N,NOLAN A,OMURO A,REID E,WANG C,MANNIS G. LONG TERM SURVIVAL IN AIDS RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. NEURO ONCOL 2017;19 (1):99-108.",53,YR,,M,Y,,,20170518,,OT,US,US,EFAVIRENZ,Alanine aminotransferase increased;Off label use,135605991,OT,,,,,,,,,135605991,1,Central nervous system lymphoma
13561285,135612851,1,I,,20170508,20170518,20170518,EXP,,US-FRESENIUS KABI-FK201704164,FRESENIUS KABI,"GUPTA N,NOLAN A,OMURO A,REID E,WANG C,MANNIS G. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. . NEURO-ONCOL 2017;19 (1):99-108.",65,YR,,M,Y,,,20170518,,OT,US,US,EFAVIRENZ,Herpes virus infection;Neutropenia,135612851,OT,,,,,,,,,135612851,1,Central nervous system lymphoma
13561304,135613041,1,I,,20170508,20170518,20170518,EXP,,US-FRESENIUS KABI-FK201704167,FRESENIUS KABI,"GUPTA N,NOLAN A,OMURO A,REID E,WANG C,MANNIS G. LONG-TERM SURVIVAL IN AIDS-RELATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. . NEURO-ONCOL 2017;19 (1):99-108.",51,YR,,M,Y,,,20170518,,OT,US,US,EFAVIRENZ,Alanine aminotransferase increased;Aspartate aminotransferase increased;Neutropenia;Off label use;Renal failure,135613041,OT,,,,,,,,,135613041,1,Central nervous system lymphoma
13561491,135614911,1,I,201702,20170509,20170518,20170518,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-042597,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,70,KG,20170518,,OT,CN,CN,EFAVIRENZ,Abdominal distension;Asthenia;Decreased appetite;Food aversion;Hepatic function abnormal,135614911,HO,,,135614911,1,20160423,,,,135614911,1,Acquired immunodeficiency syndrome
13565295,135652951,1,I,,20170515,20170519,20170519,EXP,,ZA-MYLANLABS-2017M1029650,MYLAN,,,,,,Y,,,20170519,,CN,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Corneal opacity;Foetal exposure during pregnancy,135652951,CA,,,,,,,,,135652951,1,HIV infection
13566045,135660451,1,I,,20170510,20170520,20170520,EXP,,US-DRREDDYS-USA/USA/17/0090741,DR REDDYS,"AZAR M, MALINIS M, MOSS J, FORMICA R, VILLANUEVA N. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT J STD AIDS. 2017;28(5):447-58.",,,,,Y,,,20170521,,OT,COUNTRY NOT SPECIFIED,US,efavirenz,Transplant failure,135660451,OT,,,,,,,,,135660451,1,Immunosuppression
13566048,135660481,1,I,,20170510,20170520,20170520,EXP,,US-DRREDDYS-USA/USA/17/0090737,DR REDDYS,"AZAR M, MALINIS M, MOSS J, FORMICA R, VILLANUEVA N. INTEGRASE STRAND TRANSFERASE INHIBITORS: THE PREFERRED ANTIRETROVIRAL REGIMEN IN HIV-POSITIVE RENAL TRANSPLANTATION. INT J STD AIDS. 2017;28(5):447-58.",,,,,Y,,,20170521,,OT,COUNTRY NOT SPECIFIED,US,efavirenz,Abdominal abscess;Bacteraemia;Chronic allograft nephropathy;Device related infection;Enterocutaneous fistula;Herpes zoster meningoencephalitis;Septic shock;Transplant failure,135660481,OT,,,,,,,,,135660481,1,Immunosuppression
13569392,135693921,1,I,,20170515,20170522,20170522,EXP,,US-GILEAD-2017-0273449,GILEAD,,50,YR,A,M,Y,,,20170522,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Diabetes mellitus;Diarrhoea,135693921,OT,,,,,,,,,135693921,1,HIV infection
13569652,135696522,2,F,20170419,20170525,20170522,20170605,EXP,GB-MHRA-EYC 00158567,GB-GILEAD-2017-0273109,GILEAD,,55,YR,A,F,Y,64.6,KG,20170605,,PH,GB,GB,EFAVIRENZ,Headache;Papule;Product physical issue;Product taste abnormal;Rash erythematous;Rash pruritic,135696522,OT,,,135696522,1,20170418,20170503,,,135696522,1,Asymptomatic HIV infection
13570909,135709091,1,I,,20170508,20170523,20170523,EXP,,US-HETERO LABS LTD-2021082,HETERO,,65,YR,,M,Y,,,20170523,,OT,US,US,Efavirenz\ Emtricitabine\Tenofovir,Herpes zoster;Neutropenia,135709091,OT,,,,,,,,,135709091,1,HIV infection
13570921,135709211,1,I,,20170515,20170523,20170523,EXP,,ZA-HETERO LABS LTD-2021083,HETERO,,,,,,Y,,,20170523,,PH,ZA,ZA,Efavirenz\ Emtricitabine\Tenofovir,Corneal opacity;Exposure during pregnancy;Maternal drugs affecting foetus,135709211,OT,,,,,,,,,135709211,1,Product used for unknown indication
13573712,135737122,2,F,,20170606,20170523,20170612,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-044373,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20170612,,CN,ZA,ZA,EFAVIRENZ,Corneal opacity congenital;Foetal exposure during pregnancy,135737122,CA,,,,,,,,,135737122,1,Product used for unknown indication
13576960,135769601,1,I,,20170516,20170524,20170524,EXP,,US-LPDUSPRD-20170665,LUITPOLD,GRIFFITH D.PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT..OPEN FORUM INFECTIOUS DISEASES.2017;4(1):1-4.,24,YR,A,M,Y,,,20170524,,OT,US,US,EFAVIRENZ,Coronary artery stenosis;Hypokalaemia;Myocardial infarction,135769601,HO,,,,,,,,,,,
13581524,135815241,1,I,,20170518,20170525,20170525,EXP,,US-GLAXOSMITHKLINE-US2017GSK079150,GLAXOSMITHKLINE,"ALI M S, CIFTCI FD, KOORAGAYALU S, MBA B, KOHLI A, GHORI U ET AL.. AN UNUSUAL COMPLICATION OF INHALED CORTICOSTEROIDS IN AN HIV INFECTED PATIENT. 113TH INTERNATIONAL CONFERENCE OF THE ATS. 2017",58,YR,,M,Y,,,20170525,,OT,US,US,EFAVIRENZ,Fall;Muscular weakness;Myopathy,135815241,HO,,,,,,,,,135815241,1,Chronic obstructive pulmonary disease
13582798,135827981,1,I,,20170517,20170525,20170525,EXP,,US-GILEAD-2017-0274081,GILEAD,,34,YR,A,M,Y,,,20170525,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise,135827981,HO,,,,,,,,,135827981,1,HIV infection
13583140,135831402,2,F,20160626,20170531,20170525,20170606,EXP,,ZA-GILEAD-2017-0273804,GILEAD,,34,YR,A,F,Y,,,20170606,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy;Subchorionic haemorrhage,135831402,OT,,,135831402,1,20130415,,,,135831402,1,HIV infection
13583149,135831493,3,F,,20170615,20170525,20170627,EXP,,TR-GILEAD-2017-0273882,GILEAD,"INKAYA AC, ERSOY EO, OCAL S, UNAL S. HIV POSITIVE PATIENT WITH RESPIRATORY INSUFFICIENCY. FLORA. 2016;21(4):182-185",53,YR,A,M,Y,,,20170627,,OT,TR,TR,EFAVIRENZ,Cough;HIV associated nephropathy;Myalgia;Nephropathy toxic;Productive cough;Pulmonary embolism;Pyrexia;Respiratory distress;Vena cava thrombosis;Vomiting,135831493,OT,,,,,,,,,135831493,1,Product used for unknown indication
13583409,135834091,1,I,20170407,20170518,20170526,20170526,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-044557,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,,,20170526,,MD,FR,FR,SUSTIVA,Abnormal behaviour;Aggression;Irritability,135834091,OT,,,135834091,1,20120104,20170407,,,135834091,1,Product used for unknown indication
13584642,135846421,1,I,,20170515,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09253,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846421,OT,,,,,,,,,135846421,1,Prophylaxis against HIV infection
13584663,135846631,1,I,,20170515,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09252,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846631,OT,,,,,,,,,135846631,1,Prophylaxis against HIV infection
13584664,135846641,1,I,,20170515,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09251,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846641,OT,,,,,,,,,135846641,1,Prophylaxis against HIV infection
13584671,135846711,1,I,,20170515,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09249,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526,,OT,US,US,Efavirenz,Exposure during pregnancy;Virologic failure,135846711,OT,,,,,,,,,135846711,1,Prophylaxis against HIV infection
13584679,135846791,1,I,,20170515,20170526,20170526,EXP,,US-CIPLA LTD.-2017US09250,CIPLA,"CURRIER JS, BRITTO P, HOFFMAN RM, BRUMMEL S, MASHETO G, JOAO E ET AL.,. RANDOMIZED TRIAL OF STOPPING OR CONTINUING ART AMONG POSTPARTUM WOMEN WITH PRE-ART CD4 }/= 400 CELLS/MM3. PLOS ONE. 2017;12(5):1 TO 15",,,,,Y,,,20170526,,OT,US,US,Efavirenz,Drug resistance;Exposure during pregnancy;Virologic failure,135846791,OT,,,,,,,,,135846791,1,Prophylaxis against HIV infection
13586858,135868581,1,I,,20140129,20170526,20170526,PER,,US-ROCHE-1342253,ROCHE,,,,,M,Y,,,20170526,,PH,US,US,EFAVIRENZ,Drug dose omission;No adverse event,,,,,135868581,1,200601,,,,135868581,1,Cytomegalovirus chorioretinitis
13588725,135887251,1,I,,20170515,20170529,20170529,EXP,,ZA-CIPLA LTD.-2017ZA08909,CIPLA,,,,,,Y,,,20170529,,CN,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Corneal opacity;Foetal exposure during pregnancy,135887251,CA,,,,,,,,,,,
13588726,135887261,1,I,,20170517,20170529,20170529,EXP,,KE-CIPLA LTD.-2017KE09227,CIPLA,,,,,,Y,,,20170529,,OT,KE,KE,TENOFOVIR/LAMIVUDINE/EFAVIRENZ,Left ventricular dysfunction;Neurosyphilis,135887261,HO,,,,,,,,,135887261,1,HIV infection
13589185,135891851,1,I,,20160718,20170529,20170529,PER,,US-STRIDES ARCOLAB LIMITED-2016SP010742,STRIDES,"MAKADZANGE AT, HIGGINS-BIDDLE M, CHIMUKANGARA B, BIRRI R, GORDON M, MAHLANZA T, MCHUGH G, VAN DIJK JH, BWAKURA-DANGAREMBIZI M, NDUNGU T, MASIMIREMBWA C, PHELPS B, AMZEL A, OJIKUTU BO, WALKER BD, NDHL. CLINICAL, VIROLOGIC, IMMUNOLOGIC OUTCOMES AND EMERGING HIV DRUG RESISTANCE PATTERNS IN CHILDREN AND ADOLESCENTS IN PUBLIC ART CARE IN ZIMBABWE.. PLOS ONE.. 2015;10(12):E0144057.",,,,,Y,,,20170529,,OT,US,US,EFAVIRENZ W/LAMIVUDINE/STAVUDINE;EFAVIRENZ W/LAMIVUDINE/ZIDOVUDINE,Virologic failure,135891851,OT,,,,,,,,,135891851,1,HIV infection
13595320,135953201,1,I,,20170516,20170531,20170531,EXP,,US-CIPLA LTD.-2017US09895,CIPLA,,,,,,Y,,,20170531,,CN,US,US,Tenofovir/Emtricitabine/Efavirenz,Beta haemolytic streptococcal infection;Exposure during pregnancy,135953201,OT,,,,,,,,,135953201,1,HIV infection
13595329,135953291,1,I,,20170516,20170531,20170531,EXP,,US-CIPLA LTD.-2017US09896,CIPLA,,,,,,Y,,,20170531,,CN,US,US,Tenofovir/Emtricitabine/Efavirenz,Foetal exposure during pregnancy;Polydactyly,135953291,CA,,,,,,,,,,,
13597527,135975271,1,I,,20161123,20170531,20170531,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019454,STRIDES,"COHAN D, MWESIGWA J, NATUREEBA P, ALIBA LUWEDDE F, ADES V, PLENTY A ET AL. WHO OPTION B+: EARLY EXPERIENCE OF ANTIRETROVIRAL THERAPY SEQUENCING AFTER CESSATION OF BREASTFEEDING  AND RISK OF DERMATOLOGIC TOXICITY. J ACQUIR IMMUNE DEFIC SYNDR. 2013;62(3):E101-3",,,,,Y,,,20170531,,OT,US,US,EFAVIRENZ,Erythema;Rash macular;Skin toxicity,135975271,HO,,,,,,,,,135975271,1,HIV infection
13597530,135975301,1,I,,20161123,20170531,20170531,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019324,STRIDES,"VALLABHANENI S, CHANDY S, HEYLEN E, EKSTRAND ML. EVALUATION OF WHO IMMUNOLOGIC CRITERIA FOR TREATMENT FAILURE: IMPLICATIONS FOR DETECTION OF VIROLOGIC FAILURE, EVOLUTION OF DRUG RESISTANCE AND CHOICE OF SECOND-LINE THERAPY IN INDIA. J INT AIDS SOC. 2013;16:18449",,,,,Y,,,20170531,,OT,US,US,EFAVIRENZ,Drug resistance;Virologic failure,135975301,OT,,,,,,,,,135975301,1,HIV infection
13598440,135984401,1,I,20100126,20170516,20170531,20170531,EXP,,US-MYLANLABS-2017M1032035,MYLAN,,,,,,Y,,,20170531,,OT,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Foetal exposure during pregnancy;Polydactyly,135984401,OT,,,,,,,,,135984401,1,Product used for unknown indication
13599243,135992431,1,I,20170412,20170519,20170531,20170531,EXP,,MW-GILEAD-2017-0274939,GILEAD,,39,YR,A,M,Y,,,20170531,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,135992431,OT,,,135992431,1,20170328,20170411,,,135992431,1,Kaposi's sarcoma AIDS related
13600474,136004741,1,I,,20161123,20170601,20170601,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019458,STRIDES,"COHAN D, MWESIGWA J, NATUREEBA P, ALIBA LUWEDDE F, ADES V, PLENTY A ET AL. WHO OPTION B+: EARLY EXPERIENCE OF ANTIRETROVIRAL THERAPY SEQUENCING AFTER CESSATION OF BREASTFEEDING  AND RISK OF DERMATOLOGIC TOXICITY. J ACQUIR IMMUNE DEFIC SYNDR. 2013;62(3):E101-3",,,,,Y,,,20170601,,OT,US,US,EFAVIRENZ,Pruritus generalised;Rash maculo-papular;Skin toxicity,,,,,,,,,,,136004741,1,HIV infection
13600532,136005321,1,I,,20161123,20170601,20170601,PER,,US-STRIDES ARCOLAB LIMITED-2016SP019456,STRIDES,"COHAN D, MWESIGWA J, NATUREEBA P, ALIBA LUWEDDE F, ADES V, PLENTY A ET AL. WHO OPTION B+: EARLY EXPERIENCE OF ANTIRETROVIRAL THERAPY SEQUENCING AFTER CESSATION OF BREASTFEEDING  AND RISK OF DERMATOLOGIC TOXICITY. J ACQUIR IMMUNE DEFIC SYNDR. 2013;62(3):E101-3",,,,,Y,,,20170601,,OT,US,US,EFAVIRENZ,Conjunctival hyperaemia;Rash maculo-papular;Skin toxicity,,,,,,,,,,,136005321,1,HIV infection
13607637,136076371,1,I,,20170518,20170602,20170602,EXP,,MY-MYLANLABS-2017M1032624,MYLAN,"KHAN KU, KHAN AH, SULAIMAN SA, SOO CT, AHMAD SI. UNUSUAL CASE OF LAMIVUDINE-ASSOCIATED SKIN RASHES IN AN HIV/AIDS PATIENT: A CASE PRESENTATION. ARCH-PHARMACY-PRACTICE 2017;8(2):82-83.",,,,,Y,,,20170602,,OT,MY,MY,EFAVIRENZ,Myalgia;Pyrexia;Rash,136076371,HO,,,,,,,,,136076371,1,HIV infection
13610106,136101061,1,I,,20170522,20170604,20170604,EXP,,US-HETERO LABS LTD-2021533,HETERO,"FONG PS, FLYNN DM, EVANS CD, KORTHUIS PT. INTEGRASE STRAND TRANSFER INHIBITOR-ASSOCIATED DIABETES MELLITUS: A CASE REPORT. INT-J-STD-AIDS 2017; 28(6):626-628.",44,YR,,M,Y,,,20170604,,OT,US,US,Efavirenz,Blood triglycerides increased;Diabetes mellitus;Hyperglycaemia;Insomnia,136101061,OT,,,,,,,,,136101061,1,HIV infection
13610109,136101091,1,I,,20170524,20170604,20170604,EXP,,US-HETERO LABS LTD-2021534,HETERO,,,,,,Y,2.98,KG,20170604,,OT,US,US,Efavirenz+Emtricitabine+Tenofovir,Maternal drugs affecting foetus;Polydactyly,136101091,OT,,,,,,,,,136101091,1,HIV infection
13610376,136103761,1,I,20170528,,20170602,20170602,DIR,FDA-CDER-CTU-2017-34014,,FDA-CTU,,63,YR,,M,N,,,20170602,N,OT,US,US,SUSTIVA,Computerised tomogram abnormal;Liver disorder;Vertebral lesion,,,136103761,HP,,,,,,,,,
13612571,136125712,2,F,,20170606,20170605,20170612,EXP,,TR-GILEAD-2017-0275386,GILEAD,,34,YR,A,M,Y,,,20170612,,MD,TR,TR,EFAVIRENZ,Osteopenia;Osteoporosis,136125712,OT,,,,,,,,,136125712,1,HIV infection
13614049,136140491,1,I,,20170529,20170606,20170606,EXP,,MY-HETERO LABS LTD-2021582,HETERO,,43,YR,,F,Y,,,20170606,,OT,MY,MY,Efavirenz,Myalgia;Pyrexia;Rash maculo-papular;Rash pruritic,136140491,HO,,,,,,,,,136140491,1,HIV infection
13619822,136198221,1,I,,20170529,20170606,20170606,EXP,,DK-ROCHE-1942164,ROCHE,"BORGES A, HOY J, FLORENCE E, FLORENCE D, STELLBRINK H, UZDAVINIENE V, TOMAZIC J, GARGALIANOS-KAKOLYRIS P, SCHMID P, ORKIN C, PEDERSEN C, LEEN C, PRADIER C, MULCAHY F, RIDOLFO A, STAUB T, MALTEZ F, WEBER R, FLAMHOLC L, KYSELYOVA G, LUNDGREN J AND MOCROFT A.    ANTIRETROVIRALS, FRACTURES, AND OSTEONECROSIS IN A LARGE INTERNATIONAL HIV COHORT. CLINICAL INFECTIOUS DISEASES 2017 MAY 15;64 (10):1413-1421.",,,,,Y,,,20170607,,MD,DK,DK,EFAVIRENZ,Osteonecrosis;Osteoporotic fracture,136198221,OT,,,,,,,,,136198221,1,HIV infection
13622213,136222131,1,I,200802,20070531,20170607,20170607,PER,,US-ROCHE-500022,ROCHE,,56,YR,,M,Y,155,KG,20170608,,CN,US,US,SUSTIVA,Accidental exposure to product;Complication associated with device;No adverse event,,,,,,,,,,,136222131,1,HIV infection
13634024,136340241,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10195,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340241,OT,,,,,,,,,136340241,1,HIV infection
13634065,136340651,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10201,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340651,OT,,,,,,,,,136340651,1,HIV infection
13634085,136340851,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10199,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340851,OT,,,,,,,,,136340851,1,HIV infection
13634099,136340991,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10200,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136340991,OT,,,,,,,,,136340991,1,HIV infection
13634114,136341141,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10198,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341141,OT,,,,,,,,,136341141,1,HIV infection
13634128,136341281,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10197,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341281,OT,,,,,,,,,136341281,1,HIV infection
13634141,136341411,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10196,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341411,OT,,,,,,,,,136341411,1,HIV infection
13634190,136341901,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10120,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136341901,OT,,,,,,,,,136341901,1,HIV infection
13634201,136342011,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10225,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Virologic failure,136342011,OT,,,,,,,,,136342011,1,HIV infection
13634365,136343651,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10202,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Drug resistance;Virologic failure,136343651,OT,,,,,,,,,136343651,1,HIV infection
13634381,136343811,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10203,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Adverse event,136343811,OT,,,,,,,,,136343811,1,HIV infection
13634426,136344261,1,I,,20170526,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09921,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL.,. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609,,OT,US,US,Efavirenz,Death,136344261,DE,,,,,,,,,136344261,1,HIV infection
13634432,136344321,1,I,,20170526,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09922,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL.,. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609,,OT,US,US,Efavirenz,Death,136344321,DE,,,,,,,,,136344321,1,HIV infection
13634476,136344761,1,I,,20170526,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09923,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL;. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609,,OT,US,US,Efavirenz,Death,136344761,DE,,,,,,,,,136344761,1,HIV infection
13634479,136344791,1,I,,20170526,20170609,20170609,EXP,,US-CIPLA LTD.-2017US09924,CIPLA,"COLE SR, EDWARDS JK, HALL HI, BROOKHART MA, MATHEWS WC, MOORE RD, ET AL;. INCIDENT AIDS OR DEATH AFTER INITIATION OF HUMAN IMMUNODEFICIENCY VIRUS TREATMENT REGIMENS INCLUDING RALTEGRAVIR OR EFAVIRENZ AMONG ADULTS IN THE UNITED STATES. CLINICAL INFECTIOUS DISEASES. 2017;1 TO 6",,,,,Y,,,20170609,,OT,US,US,Efavirenz,Death,136344791,DE,,,,,,,,,136344791,1,HIV infection
13634565,136345651,1,I,,20170526,20170609,20170609,EXP,,ZM-CIPLA LTD.-2017ZM10147,CIPLA,"MOORE CB, CAPPARELLI EV, SAMSON P, BWAKURA-DANGAREMBIZI M, JEAN-PHILIPPE P, WORRELL C ET AL.,. CYP2B6 GENOTYPE-DIRECTED DOSING IS REQUIRED FOR OPTIMAL EFAVIRENZ EXPOSURE IN CHILDREN 3-36 MONTHS WITH HIV INFECTION. AIDS. 2017;31(8):1129 TO 1136",,,,,Y,,,20170609,,OT,ZM,ZM,Efavirenz,Tuberculosis,136345651,OT,,,,,,,,,136345651,1,HIV infection
13634615,136346152,2,F,,20170620,20170609,20170630,EXP,,ZM-CIPLA LTD.-2017ZM10131,CIPLA,"MOORE CB, CAPPARELLI EV, SAMSON P, BWAKURA-DANGAREMBIZI M, JEAN-PHILIPPE P, WORRELL C ET AL.,. CYP2B6 GENOTYPE-DIRECTED DOSING IS REQUIRED FOR OPTIMAL EFAVIRENZ EXPOSURE IN CHILDREN 3-36 MONTHS WITH HIV INFECTION. AIDS. 2017;31 (8):1129 TO 1136",,,,,Y,,,20170630,,OT,ZM,ZM,Efavirenz,Lipase increased,136346152,OT,,,,,,,,,136346152,1,HIV infection
13634673,136346731,1,I,,20170526,20170609,20170609,EXP,,ZM-CIPLA LTD.-2017ZM10115,CIPLA,"MOORE CB, CAPPARELLI EV, SAMSON P, BWAKURA-DANGAREMBIZI M, JEAN-PHILIPPE P, WORRELL C ET AL.,. CYP2B6 GENOTYPE-DIRECTED DOSING IS REQUIRED FOR OPTIMAL EFAVIRENZ EXPOSURE IN CHILDREN 3-36 MONTHS WITH HIV INFECTION. AIDS. 2017;31(8):1129 TO 1136",,,,,Y,,,20170609,,OT,ZM,ZM,Efavirenz,Tuberculosis,136346731,OT,,,,,,,,,136346731,1,HIV infection
13635053,136350531,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10204,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Adverse event,136350531,OT,,,,,,,,,136350531,1,HIV infection
13635939,136359391,1,I,,20170526,20170609,20170609,EXP,,MX-CIPLA LTD.-2017MX10205,CIPLA,,,,,,Y,,,20170609,,OT,ZM,MX,Efavirenz,Epilepsy,136359391,OT,,,,,,,,,136359391,1,HIV infection
13636714,136367141,1,I,,20170605,20170609,20170609,EXP,,BF-STRIDES ARCOLAB LIMITED-2017SP009182,STRIDES,,,,,,Y,,,20170609,,OT,FR,BF,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,136367141,OT,,,,,,,,,136367141,1,HIV infection
13636901,136369011,1,I,,20170605,20170609,20170609,EXP,,GB-STRIDES ARCOLAB LIMITED-2017SP009286,STRIDES,,,,,,Y,,,20170609,,OT,GB,GB,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,136369011,OT,,,,,,,,,136369011,1,HIV infection
13637003,136370031,1,I,,20170605,20170609,20170609,EXP,,GB-STRIDES ARCOLAB LIMITED-2017SP009287,STRIDES,,,,,,Y,,,20170609,,OT,GB,GB,EFAVIRENZ,Drug resistance;Viral mutation identified;Virologic failure,136370031,OT,,,,,,,,,136370031,1,HIV infection
13643941,136439411,1,I,,20160512,20170612,20170612,EXP,,US-GILEAD-2016-0214044,GILEAD,,49,YR,A,F,Y,,,20170612,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood potassium decreased;Drug dose omission;Facial paralysis;Headache;Hypertension,136439411,HO,,,136439411,1,2011,,,,136439411,1,HIV infection
13646342,136463421,1,I,,20170601,20170613,20170613,EXP,,ES-ACTELION-A-CH2017-154739,ACTELION,,,,,M,Y,,,20170613,,MD,ES,ES,SUSTIVA,Blood creatinine increased;Drug interaction;Renal failure,136463421,OT,,,136463421,1,20160506,20160717,,,136463421,1,Pulmonary arterial hypertension
13649428,136494281,1,I,,20170530,20170613,20170613,EXP,,US-AUROBINDO-AUR-APL-2017-35325,AUROBINDO,,,,N,,Y,2.9,KG,20170613,,OT,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Foetal exposure during pregnancy;Polydactyly,136494281,CA,,,,,,,,,136494281,1,HIV infection
13651384,136513841,1,I,20170504,20170602,20170614,20170614,EXP,,ZA-GILEAD-2017-0276651,GILEAD,,34,YR,A,F,Y,46,KG,20170614,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthma,136513841,HO,,,136513841,1,20160217,20151210,,,136513841,1,HIV infection
13655074,136550741,1,I,,20170612,20170615,20170615,EXP,2017-0252414,UG-STRIDES ARCOLAB LIMITED-2017SP009461,STRIDES,,,,,,Y,,,20170615,,OT,UG,UG,EFAVIRENZ,Death;Exposure during pregnancy,136550741,OT,,,,,,,,,136550741,1,Product used for unknown indication
13656806,136568061,1,I,,20170605,20170615,20170615,EXP,,DE-GILEAD-2017-0277975,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568061,OT,,,,,,,,,136568061,1,HIV infection
13656826,136568261,1,I,,20170605,20170615,20170615,EXP,,DE-GILEAD-2017-0277977,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568261,OT,,,,,,,,,136568261,1,HIV infection
13656891,136568911,1,I,,20170605,20170615,20170615,EXP,,DE-GILEAD-2017-0277976,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568911,OT,,,,,,,,,136568911,1,HIV infection
13656893,136568931,1,I,,20170605,20170615,20170615,EXP,,DE-GILEAD-2017-0277244,GILEAD,"RADMER S, ANDRESEN JR, ANDRESEN R. RECURRENT BONE MARROW OEDEMAS AND INSUFFICIENCY FRACTURES IN HIV PATIENTS ON ANTIVIRAL THERAPY. 44TH ANNUAL EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS. 2017;100:S132",,,A,M,Y,,,20170615,,MD,DE,DE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone marrow oedema,136568931,OT,,,,,,,,,136568931,1,HIV infection
13657466,136574661,1,I,2015,20170608,20170615,20170615,EXP,,US-GILEAD-2017-0278017,GILEAD,,52,YR,A,M,Y,,,20170615,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Accident at work;Back injury,136574661,OT,,,,,,,,,136574661,1,HIV infection
13658831,136588312,2,F,20170317,20170619,20170616,20170623,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-051773,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,80,KG,20170623,,OT,CN,CN,EFAVIRENZ,Macule,136588312,HO,,,136588312,1,20170310,20170320,,,136588312,1,HIV infection
13658931,136589311,1,I,,20170612,20170616,20170616,EXP,,TH-STRIDES ARCOLAB LIMITED-2017SP009459,STRIDES,,,,,,Y,,,20170616,,OT,TH,TH,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,136589311,OT,,,,,,,,,136589311,1,Product used for unknown indication
13658943,136589431,1,I,,20170612,20170616,20170616,EXP,,BR-STRIDES ARCOLAB LIMITED-2017SP009471,STRIDES,,,,,,Y,,,20170616,,OT,BR,BR,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,136589431,OT,,,,,,,,,136589431,1,Product used for unknown indication
13670578,136705781,1,I,,20170605,20170620,20170620,EXP,,"US-LANNETT COMPANY, INC.-US-2017LAN000844",LANNETT,"GRIFFITH DC, ARONIS KN, OROZCO AM, TRAILL TA, MANABE YC, AGWU AL. PREMATURE CORONARY ARTERY DISEASE AND ST-ELEVATION MYOCARDIAL INFARCTION IN A 24-YEAR-OLD MAN WITH PERINATALLY ACQUIRED HUMAN IMMUNODEFICIENCY VIRUS: A CASE REPORT. OPEN-FORUM-INFECT-DIS. 2017;4(1):1-4",24,YR,,M,Y,,,20170620,,MD,US,US,EFAVIRENZ,Acute myocardial infarction;Arteriosclerosis,136705781,HO,,,,,,,,,136705781,1,Antiretroviral therapy
13674491,136744911,1,I,201704,20170612,20170621,20170621,EXP,,CN-GILEAD-2017-0278700,GILEAD,,46,YR,A,M,Y,68,KG,20170621,,OT,CN,CN,EFAVIRENZ,Liver injury;Pruritus,136744911,HO,,,136744911,1,20170402,20170418,,,136744911,1,HIV carrier
13674712,136747121,1,I,,20170608,20170621,20170621,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-054682,BRISTOL MYERS SQUIBB,,,,,,Y,,,20170621,,OT,IN,IN,EFAVIRENZ,Hypersensitivity vasculitis,136747121,OT,,,,,,,,,136747121,1,HIV test positive
13675272,136752721,1,I,,20170612,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009653,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136752721,OT,,,,,,,,,136752721,1,HIV infection
13675301,136753011,1,I,,20170612,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009670,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753011,OT,,,,,,,,,136753011,1,HIV infection
13675316,136753161,1,I,,20170612,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009646,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753161,OT,,,,,,,,,136753161,1,HIV infection
13675322,136753221,1,I,,20170612,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009628,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753221,OT,,,,,,,,,136753221,1,HIV infection
13675341,136753411,1,I,,20170612,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009654,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753411,OT,,,,,,,,,136753411,1,HIV infection
13675354,136753541,1,I,,20170612,20170621,20170621,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009639,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170621,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136753541,OT,,,,,,,,,136753541,1,HIV infection
13676619,136766191,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10920,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136766191,OT,,,,,,,,,136766191,1,HIV infection WHO clinical stage IV
13676787,136767871,1,I,,20170612,20170622,20170622,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009632,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170622,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136767871,OT,,,,,,,,,136767871,1,HIV infection
13676800,136768001,1,I,,20170612,20170622,20170622,EXP,,SE-STRIDES ARCOLAB LIMITED-2017SP009676,STRIDES,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12(6):E0178942",,,,,Y,,,20170622,,OT,SE,SE,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,136768001,OT,,,,,,,,,136768001,1,HIV infection
13676821,136768211,1,I,20170525,,20170621,20170621,DIR,FDA-CDER-CTU-2017-38159,,FDA-CTU,,33,YR,,M,N,,,20170529,Y,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DP;LAMIVUDINE/ABACAVIR/EFAVIRENZ,Acute kidney injury;Chills;Feeling hot;Haemoglobin decreased;Pain in extremity;Platelet count decreased;Skin ulcer,136768211,LT,136768211,HP,136768211,1,20170227,20170504,,,136768211,1,Kaposi's sarcoma
13676834,136768341,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10931,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136768341,OT,,,,,,,,,136768341,1,HIV infection WHO clinical stage III
13676911,136769111,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10936,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136769111,OT,,,,,,,,,136769111,1,HIV infection WHO clinical stage II
13676989,136769891,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10932,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136769891,OT,,,,,,,,,136769891,1,HIV infection WHO clinical stage III
13677049,136770491,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10953,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136770491,OT,,,,,,,,,136770491,1,HIV infection WHO clinical stage IV
13677094,136770941,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10933,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136770941,OT,,,,,,,,,136770941,1,HIV infection WHO clinical stage II
13677134,136771341,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10935,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136771341,OT,,,,,,,,,136771341,1,HIV infection WHO clinical stage III
13677150,136771501,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10934,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136771501,OT,,,,,,,,,136771501,1,HIV infection WHO clinical stage III
13677151,136771511,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10954,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136771511,OT,,,,,,,,,136771511,1,HIV infection WHO clinical stage IV
13677347,136773471,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10922,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773471,OT,,,,,,,,,136773471,1,HIV infection WHO clinical stage IV
13677350,136773501,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10925,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773501,OT,,,,,,,,,136773501,1,HIV infection WHO clinical stage II
13677351,136773511,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10924,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773511,OT,,,,,,,,,136773511,1,HIV infection WHO clinical stage II
13677353,136773531,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10923,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773531,OT,,,,,,,,,136773531,1,HIV infection WHO clinical stage IV
13677356,136773561,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10956,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773561,OT,,,,,,,,,136773561,1,HIV infection WHO clinical stage IV
13677359,136773591,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10921,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773591,OT,,,,,,,,,136773591,1,HIV infection WHO clinical stage III
13677371,136773711,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10926,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773711,OT,,,,,,,,,136773711,1,HIV infection WHO clinical stage IV
13677379,136773791,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10927,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773791,OT,,,,,,,,,136773791,1,HIV infection WHO clinical stage III
13677380,136773801,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10928,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773801,OT,,,,,,,,,136773801,1,HIV infection WHO clinical stage II
13677386,136773861,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10929,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773861,OT,,,,,,,,,136773861,1,HIV infection WHO clinical stage III
13677389,136773891,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10930,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136773891,OT,,,,,,,,,136773891,1,HIV infection WHO clinical stage III
13677393,136773931,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10955,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Treatment failure,136773931,OT,,,,,,,,,136773931,1,HIV infection WHO clinical stage IV
13677402,136774021,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10958,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136774021,OT,,,,,,,,,136774021,1,HIV infection WHO clinical stage IV
13677515,136775151,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10940,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775151,OT,,,,,,,,,136775151,1,HIV infection WHO clinical stage III
13677516,136775161,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10939,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775161,OT,,,,,,,,,136775161,1,HIV infection WHO clinical stage II
13677517,136775171,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10941,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775171,OT,,,,,,,,,136775171,1,HIV infection WHO clinical stage IV
13677519,136775191,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10975,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775191,OT,,,,,,,,,136775191,1,HIV infection WHO clinical stage III
13677520,136775201,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10945,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775201,OT,,,,,,,,,136775201,1,HIV infection WHO clinical stage III
13677527,136775271,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10976,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775271,OT,,,,,,,,,136775271,1,HIV infection WHO clinical stage III
13677552,136775521,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10978,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775521,OT,,,,,,,,,136775521,1,HIV infection WHO clinical stage III
13677564,136775641,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10981,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775641,OT,,,,,,,,,136775641,1,HIV infection WHO clinical stage II
13677565,136775651,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10980,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775651,OT,,,,,,,,,136775651,1,HIV infection WHO clinical stage II
13677568,136775681,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10979,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775681,OT,,,,,,,,,136775681,1,HIV infection WHO clinical stage II
13677591,136775911,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10937,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775911,OT,,,,,,,,,136775911,1,HIV infection WHO clinical stage III
13677592,136775921,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10938,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136775921,OT,,,,,,,,,136775921,1,HIV infection WHO clinical stage IV
13677600,136776001,1,I,,20170608,20170622,20170622,EXP,,SE-CIPLA LTD.-2017TZ10982,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136776001,OT,,,,,,,,,136776001,1,HIV infection WHO clinical stage III
13679070,136790701,1,I,201512,20170615,20170622,20170622,EXP,,US-GILEAD-2017-0279140,GILEAD,,51,YR,A,M,Y,,,20170622,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anxiety disorder due to a general medical condition;Cardiac failure congestive;Poor quality sleep,136790701,OT,,,136790701,1,2009,,,,136790701,1,HIV infection
13680122,136801221,1,I,20170614,20170616,20170622,20170622,EXP,,US-VIFOR (INTERNATIONAL) INC.-VIT-2017-06750,VIFOR,,66,YR,,M,Y,,,20170622,,OT,US,US,SUSTIVA,Death,136801221,DE,,,136801221,1,20170405,,,,136801221,1,Hyperkalaemia
13680466,136804661,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10942,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136804661,OT,,,,,,,,,136804661,1,HIV infection WHO clinical stage IV
13680542,136805421,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10943,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136805421,OT,,,,,,,,,136805421,1,HIV infection WHO clinical stage IV
13680573,136805731,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10944,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136805731,OT,,,,,,,,,136805731,1,HIV infection WHO clinical stage IV
13680586,136805861,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10946,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136805861,OT,,,,,,,,,136805861,1,HIV infection WHO clinical stage III
13680665,136806651,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10948,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136806651,OT,,,,,,,,,136806651,1,HIV infection WHO clinical stage II
13680709,136807091,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10950,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807091,OT,,,,,,,,,136807091,1,HIV infection WHO clinical stage III
13680713,136807131,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10951,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807131,OT,,,,,,,,,136807131,1,HIV infection WHO clinical stage II
13680742,136807421,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10952,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807421,OT,,,,,,,,,136807421,1,HIV infection WHO clinical stage IV
13680743,136807431,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10957,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807431,OT,,,,,,,,,136807431,1,HIV infection
13680762,136807621,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10964,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807621,OT,,,,,,,,,136807621,1,HIV infection WHO clinical stage III
13680763,136807631,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10963,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807631,OT,,,,,,,,,136807631,1,HIV infection WHO clinical stage II
13680767,136807671,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10962,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807671,OT,,,,,,,,,136807671,1,HIV infection WHO clinical stage IV
13680773,136807731,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10961,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807731,OT,,,,,,,,,136807731,1,HIV infection WHO clinical stage III
13680775,136807751,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10960,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807751,OT,,,,,,,,,136807751,1,HIV infection WHO clinical stage IV
13680786,136807861,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10968,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807861,OT,,,,,,,,,136807861,1,HIV infection WHO clinical stage III
13680788,136807881,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10967,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807881,OT,,,,,,,,,136807881,1,HIV infection WHO clinical stage III
13680792,136807921,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10971,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F ET AL.,. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Treatment failure,136807921,OT,,,,,,,,,136807921,1,HIV infection WHO clinical stage II
13680793,136807931,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10970,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807931,OT,,,,,,,,,136807931,1,HIV infection WHO clinical stage I
13680795,136807951,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10974,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807951,OT,,,,,,,,,136807951,1,HIV infection WHO clinical stage II
13680796,136807961,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10973,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807961,OT,,,,,,,,,136807961,1,HIV infection WHO clinical stage II
13680797,136807971,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10984,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170623,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136807971,OT,,,,,,,,,136807971,1,HIV infection WHO clinical stage IV
13681219,136812191,1,I,,20170608,20170623,20170623,EXP,,SE-CIPLA LTD.-2017TZ10983,CIPLA,"SVARD J, MUGUSI S, MLOKA D, NEOGI U, MEINI G, MUGUSI F, ET AL;. DRUG RESISTANCE TESTING THROUGH REMOTE GENOTYPING AND PREDICTED TREATMENT OPTIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTED TANZANIAN SUBJECTS FAILING FIRST OR SECOND LINE ANTIRETROVIRAL THERAPY. PLOS ONE. 2017;12 (6):1 TO 13",,,,,Y,,,20170622,,OT,SE,TZ,Efavirenz,Drug resistance;Treatment failure,136812191,OT,,,,,,,,,136812191,1,HIV infection WHO clinical stage III
13682318,136823181,1,I,20150426,20160504,20170623,20170623,PER,,US-MALLINCKRODT-T201601651,MALLINCKRODT,,46,YR,,M,Y,134,KG,20170623,,OT,US,US,SUSTIVA,Pneumonia,136823181,HO,,,136823181,2,20140428,20140502,,,136823181,1,Systemic lupus erythematosus
13684970,136849702,2,F,20170608,20170616,20170623,20170628,EXP,,KE-GILEAD-2017-0279249,GILEAD,,21,YR,A,F,Y,,,20170628,,OT,KE,KE,EFAVIRENZ W/LAMIVUDINE/TENOFOVIR DISOPROXIL F;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Skin ulcer,136849702,HO,,,136849702,1,20160728,20170518,,,136849702,1,Acquired immunodeficiency syndrome
13687034,136870341,1,I,,20170609,20170623,20170623,EXP,,UG-MYLANLABS-2017M1037702,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136870341,OT,,,,,,,,,136870341,1,HIV infection
13687035,136870351,1,I,,20170609,20170623,20170623,EXP,,UG-MYLANLABS-2017M1037717,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136870351,OT,,,,,,,,,136870351,1,HIV infection
13687580,136875801,1,I,,20170609,20170624,20170624,EXP,,UG-MYLANLABS-2017M1037773,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136875801,OT,,,,,,,,,136875801,1,HIV infection
13687581,136875811,1,I,,20170609,20170624,20170624,EXP,,UG-MYLANLABS-2017M1037751,MYLAN,"BIRUNGI J, MIN JE, MULDOON KA, KALEEBU P, KING R, KHANAKWA S, ET AL. LACK OF EFFECTIVENESS OF ANTIRETROVIRAL THERAPY IN PREVENTING HIV INFECTION IN SERODISCORDANT COUPLES IN UGANDA: AN OBSERVATIONAL STUDY. PLOS-ONE 2015;10:NO. 7.",,,,,Y,,,20170623,,OT,UG,UG,EFAVIRENZ,Drug ineffective;Human immunodeficiency virus transmission,136875811,OT,,,,,,,,,136875811,1,HIV infection
13703124,137031241,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000875",LANNETT,,,,,,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137031241,OT,,,,,,,,,137031241,1,Tuberculosis
13703197,137031971,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000876",LANNETT,,34,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137031971,OT,,,,,,,,,137031971,1,Tuberculosis
13703239,137032391,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000877",LANNETT,,45,YR,,M,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137032391,OT,,,,,,,,,137032391,1,Tuberculosis
13703289,137032891,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000878",LANNETT,,25,YR,,M,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137032891,OT,,,,,,,,,137032891,1,Tuberculosis
13703317,137033171,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000879",LANNETT,,28,YR,,F,Y,,,20170629,,CN,ET,ET,EFAVIRENZ,Cholestatic liver injury,137033171,OT,,,,,,,,,137033171,1,Tuberculosis
13703351,137033511,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000880",LANNETT,,37,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137033511,OT,,,,,,,,,137033511,1,Tuberculosis
13703420,137034201,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000881",LANNETT,,28,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137034201,OT,,,,,,,,,137034201,1,Tuberculosis
13703453,137034531,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000882",LANNETT,,55,YR,,M,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137034531,OT,,,,,,,,,137034531,1,Tuberculosis
13703470,137034701,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000883",LANNETT,,45,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137034701,OT,,,,,,,,,137034701,1,Tuberculosis
13703498,137034981,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000884",LANNETT,,30,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137034981,OT,,,,,,,,,137034981,1,Tuberculosis
13703546,137035461,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000885",LANNETT,,60,YR,,M,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137035461,OT,,,,,,,,,137035461,1,Tuberculosis
13703588,137035881,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000886",LANNETT,,30,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury;Hepatotoxicity,137035881,OT,,,,,,,,,137035881,1,Tuberculosis
13703609,137036091,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000887",LANNETT,,30,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury,137036091,OT,,,,,,,,,137036091,1,Tuberculosis
13703653,137036531,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000888",LANNETT,,30,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Cholestatic liver injury;Hepatotoxicity;Mixed liver injury,137036531,OT,,,,,,,,,137036531,1,Tuberculosis
13703672,137036721,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000889",LANNETT,,31,YR,,M,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Mixed liver injury,137036721,OT,,,,,,,,,137036721,1,Tuberculosis
13703745,137037451,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000890",LANNETT,,49,YR,,M,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Mixed liver injury,137037451,OT,,,,,,,,,137037451,1,Tuberculosis
13703782,137037821,1,I,,20170616,20170629,20170629,EXP,,"SE-LANNETT COMPANY, INC.-ET-2017LAN000891",LANNETT,,38,YR,,F,Y,,,20170629,,OT,ET,ET,EFAVIRENZ,Hepatotoxicity;Mixed liver injury,137037821,OT,,,,,,,,,137037821,1,Tuberculosis
6902323,69023236,6,F,20070614,20170407,20090205,20170413,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14445084,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,,,20170413,,CN,JP,JP,EFAVIRENZ,Diabetes mellitus;Myasthenia gravis,69023236,OT,,,69023236,1,20030124,20100119,,,69023236,1,HIV infection
6971454,69714546,6,F,20020909,20170518,20090417,20170525,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-14589196,BRISTOL MYERS SQUIBB,,34,YR,,M,Y,,,20170525,,CN,JP,JP,EFAVIRENZ,Lipoatrophy;Varices oesophageal,69714546,HO,,,69714546,1,20000901,20100711,,,69714546,1,HIV infection
9702814,97028143,3,F,200809,20170616,20131121,20170623,EXP,FR-AFSSAPS-BX20080806,FR-VIIV HEALTHCARE LIMITED-B0546637A,VIIV,,51,YR,,F,Y,,,20170623,,CN,FR,FR,SUSTIVA,Abnormal sensation in eye;Alopecia;Anxiety;Arthralgia;Asthenia;Cheilitis;Conjunctival disorder;Cough;Depression;Dermatitis bullous;Dry eye;Dry mouth;Dysphagia;Hand deformity;Insomnia;Lacrimation increased;Mental disorder;Mucous membrane disorder;Nail dystrophy;Onycholysis;Orthosis user;Peripheral swelling;Peripheral vascular disorder;Photophobia;Pigmentation disorder;Pyrexia;Toxic epidermal necrolysis,97028143,LT,,,97028143,1,200201,20081007,,,97028143,1,HIV infection
9886886,98868869,9,F,20121213,20170420,20140210,20170424,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-17227166,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,38,KG,20170424,,CN,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Burning sensation;Diarrhoea;Hypokalaemia;Hyponatraemia;Malaise;Muscular weakness;Neutropenia;Pyrexia;Vomiting,98868869,OT,,,98868869,1,20121115,20131107,,,98868869,1,HIV infection
